Cell-Membrane-Permeable Conjugates for Gene Editing

Recombinant beta-helical proteins are used to enhance the delivery of genome editing systems like CRISPR-Cas9 across cell membranes, addressing inefficiencies in current methods by promoting direct membrane penetration and improving transfection efficiency.

JP7582956B2Active Publication Date: 2024-11-13CYGENICA LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
JP2021550111
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-02-27
Filing Date
2020-02-27
Publication Date
2024-11-13
Estimated Expiration
2040-02-27

AI Technical Summary

Technical Problem

Current methods for delivering gene editing machinery across cell membranes, such as CRISPR-Cas9, face inefficiencies and challenges, particularly in non-viral approaches, leading to incomplete gene delivery and potential immunoreactivity issues.

Method used

Development of recombinant beta-helical proteins linked to genome editing systems, including CRISPR-Cas9, with specific dimensions and charge profiles to enhance membrane penetration, avoiding endocytosis and improving transfection efficiency.

Benefits of technology

The beta-helical proteins facilitate efficient delivery of genome editing molecules into cells, enhancing gene editing processes by bypassing endosomal degradation and improving delivery efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007582956000007
    Figure 0007582956000007
  • Figure 0007582956000008
    Figure 0007582956000008
  • Figure 0007582956000009
    Figure 0007582956000009
Patent Text Reader

Abstract

A genome editing complex for modifying a target polynucleotide comprising a recombinant beta helix protein linked to either one or more molecules of a genome editing system or a plasmid encoding one or more molecules of the genome editing system, wherein the length of the beta helix protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure broadly relates to the field of one or more gene editing molecules delivery to the cytoplasm of cells, and in particular discloses a conjugate comprising recombinant protein linked to one or more gene editing molecules for permeating cell membrane, the method of preparing said conjugate, and its use.The present disclosure also relates to a conjugate comprising recombinant protein linked to nucleic acid or plasmid encoding one or more gene editing molecules for permeating cell membrane, the method of preparing said conjugate, and its use. [Background technology]

[0002] The cell membrane is a semipermeable membrane that separates the internal environment of a cell from its external environment. Prokaryotic and eukaryotic cell membranes differ in some properties and composition, but both are composed of a semipermeable bilayer structure of phospholipids. The semipermeable nature of the cell membrane makes it selective for the types of molecules that can permeate the cell membrane. These molecules that can permeate the cell membrane are promising for use in cell labeling, cell penetration, cell delivery, drug uptake, gene therapy, and many other applications that involve the penetration of the cell membrane.

[0003] There are certain peptides that can penetrate cell membranes and translocate into the cytosol; such peptides are called cell-penetrating peptides (CPPs). CPP conjugates, in which the CPP is linked to one or more functional molecules, have been investigated as a means of transporting various biologically active molecules across membranes. For example, insulin absorption was dramatically increased (6-8-fold) in Caco-2 cells when treated with the CPP conjugate CPP-insulin (Liang et al., Biochem. Biophys. Res. Commun.; 2005; 335(3):734-738). Similar results were seen for conjugates containing the Tat peptide (ibid.). Another study reported the use of a short amphipathic peptide carrier, Pep-1, that can penetrate membranes and deliver a variety of peptides and proteins to several cell lines (Morris et al., Nature Biotechnol., 2001, 1173-1176).

[0004] CPPs have also been used to study the efficient delivery of various anticancer drugs as drug-CPP conjugates that can penetrate cell membranes more efficiently than the drug alone due to the properties of CPPs. One such study reports the use of Tat protein conjugated with a CK2 inhibitor (P15) to treat solid tumors (Perea et al., Cancer Res. 2004, 7127-7129).

[0005] There are also some molecular transporters that can deliver molecules across cell membranes. Guanidinium-rich molecular transporters (GR-MoTrs), including peptide and non-peptide agents, have been shown to penetrate cell membranes due to the number and spatial arrangement of guanidinium groups. GR-MoTrs can enhance the delivery of various cargos, such as small molecules, metals, contrast agents, iron particles, and proteins, in mammalian cells (Wender et al., Adv. Drug Deliv. Rev. 2008, 452-472; Wender et al., Drug Discov. Today Technol. 2012, e49-e55).

[0006] US2013 / 0137644 discloses a conjugate composed of a cell-penetrating peptide, a nucleic acid, and a hydrophilic polymer that can more efficiently penetrate cell membranes. The nucleic acid used in the conjugate is described as preferably siRNA having polyethylene glycol (PEG) as a hydrophilic polymer.

[0007] US2004 / 0176282 discloses methods and uses of compositions for cellular delivery of nucleic acids, polypeptides, fluorophores, molecular complexes. The intracellular release of biologically active molecules after cell penetration is stimulated by light-activated dispersion of the complex. This system serves to suppress the biological function of molecules while they are part of the complex, but once inside the cell and light-activated, they can disperse and restore their biological activity.

[0008] In addition to and common to the delivery of all functional molecules to cells, most of the mechanisms developed for cell delivery rely on endocytosis-dependent mechanisms to gain entry into the cell. The efficiency of translocation is a major area of ​​concern in endocytosis-dependent pathways, for example, because drugs may be trapped in endosomes or degraded in lysosomes. Thus, there is a pressing need to devise novel mechanisms for penetrating cell membranes that can be more reliable and effective.

[0009] One example of a promising and widely used technology involving functional molecules crossing cell membrane barriers is genome engineering, which edits DNA (i.e., inserts, deletes, modifies, or replaces one or more nucleotides) in the genome of an organism.

[0010] One type of genome engineering is gene therapy. Gene therapy involves the delivery of a gene of interest into a cell to compensate for the abnormal activity of the gene or to provide a beneficial protein. Gene therapy has proven beneficial in the treatment of diseases such as chronic lymphocytic leukemia, X-linked SCID, multiple myeloma, and hemophilia, among others. Many life-threatening diseases have an underlying genetic cause, i.e., the disease is due to a malfunction or lack of proper function exhibited by one or more associated genes. Gene therapy has shown promise in the treatment of such conditions. However, gene therapy still faces challenges in terms of delivering the required genes across the cell membrane. To date, two approaches to deliver genes have been used, which are viral-based and non-viral-based.

[0011] Viral-based approaches for gene therapy utilize attenuated viruses as vectors in which the desired gene is cloned and transferred to the required cells through a process known as transduction. This approach has the advantage that the delivered gene is properly integrated into the genome of the cell, but it also has other drawbacks, one of which is the tendency to induce cancer in the case of improper genomic integration. Non-viral-based approaches include the use of injection of isolated DNA into cells, and the use of cationic lipids to surround plasmid DNA (lipofection). Non-viral approaches do not require the gene to be integrated into the genome and are inefficient in transferring the required gene to other cells in the tissue. Thus, gene therapy is a promising and superior technology for treating many life-threatening disorders, but it is plagued by the problem of delivery of genes to cells.

[0012] For the most common genetic diseases, such as cystic fibrosis or muscular dystrophies, effective gene therapy may remain a challenge due to the difficulty of delivering genetic material to cells. There is still no simple way to deliver genes to a significant proportion of cells in tissues such as lung epithelium or skeletal muscle (Collins et al., Proc. R. Soc. B. Vol. 282. No. 1821. The Royal Society, 2015). Therefore, there is a need for effective mechanisms of cell delivery that can significantly enhance the benefits of gene therapy and open the way to provide promising treatments for many life-threatening diseases.

[0013] A further type of genome engineering that requires functional molecules to cross the cell membrane barrier is gene or genome editing. Genome editing allows the creation of site-specific double-strand breaks at desired locations in the genome, typically using engineered nucleases. These breaks are then repaired by non-homologous end joining (NHEJ) or homologous recombination (HR) or homology-directed repair (HDR), resulting in site-specific mutations or "edits" of the genome. Known engineered nucleases include nucleic acid-guided endonucleases such as zinc finger nucleases (ZFNs), transcription activator-like effector-based nucleases (TALENs), homing endonucleases (such as ARC nucleases™), or DNA-guided endonucleases, and RNA-guided endonucleases such as, but not limited to, the clustered regularly interspaced short palindromic repeats (CRISPR) system, which is mainly based on the endonuclease Cas9.

[0014] Zinc finger nucleases (ZFNs) are a class of engineered DNA-binding proteins that facilitate targeted editing of genomes by creating double-stranded breaks in DNA at user-specified locations. Each zinc finger nuclease (ZFN) consists of two functional domains: a) a DNA-binding domain composed of two strands of finger modules, each recognizing a unique hexameric (6 bp) sequence of DNA. The two finger modules are joined together to form a zinc finger protein, each with a specificity of ≥ 24 bp; and b) a DNA-cleavage domain composed of the nuclease domain of FokI. When the DNA-binding and DNA-cleavage domains are fused together, a pair of highly specific "genomic scissors" is created.

[0015] Transcription Activator-Like Effector Nuclease (TALEN®) technology utilizes artificial restriction enzymes generated by fusing a TAL effector DNA binding domain to a DNA cleavage domain. Restriction enzymes are enzymes that cleave DNA strands at specific sequences. Transcription Activator-Like Effectors (TALEN®) can be rapidly engineered to bind to virtually any desired DNA sequence. By combining such engineered TALEN® with a DNA cleavage domain (which cleaves DNA strands), restriction enzymes can be engineered to specifically cleave any desired DNA sequence. Once these restriction enzymes are introduced into cells, they can be used for gene editing or in situ genome editing.

[0016] CRISPR gene editing utilizes a multi-component molecular system that includes an endonuclease, typically Cas or Cpf1 endonuclease, and one or more guide RNA (gRNA) molecules that can direct the nuclease to a specific genomic sequence. When the gRNA hybridizes with the genomic sequence, the endonuclease acts to cut the DNA strand. By delivering Cas9 nuclease complexed with synthetic gRNA to cells, the genome of the cell can be cut at a desired position, removing existing genes and / or adding new genes (Ledford, H., Nature, 2015, 522, 7554; Zetsche et al., Cell, 2015, 163(3), 759-771).

[0017] A key step in CRISPR technology is the delivery of gRNA and an endonuclease (such as Cas9) into the cytoplasm and / or nucleus of a target cell. The delivery of nucleic acids into a cell is called transfection. gRNA and Cas9 can be introduced either as DNA, RNA, or pre-complexed RNA and proteins called ribonucleoproteins (RNPs). Transporting foreign material across multiple cellular barriers (e.g., plasma membrane, nuclear membrane) is a challenge.

[0018] Transfection methods can be broadly categorized into physical, chemical, and viral-mediated categories. Each method has various advantages and disadvantages in terms of efficiency, throughput, equipment, skills, and cost. The choice of transfection method also depends on the format of the CRISPR components.

[0019] Transposition of the CRISPR gene editing machinery as a preformed ribonucleoprotein (CRISPR-RNP) containing the Cas9 enzyme with RNA means that no further transcription or translation is required prior to gene editing. This allows editing to be performed quickly as fewer steps are required. This may be useful in some situations, such as transient transfections, where CRISPR components are introduced into a cell but the DNA encoding the guide RNA or Cas9 is not integrated into the cell's genome. CRISPR-Cas9 can cleave the cell's genomic DNA for only a limited period of time. However, transposition of such a large and diverse set of macromolecules across the cell membrane presents unique challenges with regard to the efficiency of transfer across the cell membrane.

[0020] Adeno-associated virus particles have been commonly used as gene delivery agents, but safety issues and limited loading capacity make viral carriers a less than ideal delivery vehicle (Swiech et al., Nat. Biotechnol., 2015, 33, 102-106). Non-viral means of delivering genome editing system molecules include lipid-based vectors, lipid nanoparticles, polymer vectors, polyethyleneimine, and poly(L-lysine), to name a few, but the application of genome editing in vivo (such as by using CRISPR tools) remains a challenge due to limitations of currently used delivery approaches (Li et al., Human Gene Therapy, 2015, 26(7), 452-462; Wang et al., Proceedings of the National Academy of Sciences, 2016, 113(11), 2868-2873).

[0021] Cell-penetrating peptides are also known to transport CRISPR gene editing machinery into cells. WO2017 / 205846 describes the use of cell-penetrating peptides VEPEP-3a / b and ADGN-100a / b to facilitate transfection of CRISPR-RNPs. However, it has been shown that cell-penetrating peptides VEPEP-9 and CADY are only moderate binders, and cell-penetrating peptide VEPEP-6 interacts poorly with labeled Cas9 and labeled Cas9-gRNA complexes. Thus, it is clear that the choice of CPP is an essential determinant for the efficiency of transfection of gene editing machinery. Cell-penetrating peptides used in the literature for gene editing have limited potential use in vivo due to the disruption of Cas9 immunoreactivity and reactivity due to the strong electrostatic interactions between the positively charged CPPs and the negatively charged Cas9-gRNA complex (Analytical Biochemistry 345(2005)55-65, Int. J. Mol. Sci. 2016, 17, 626; doi:10.3390 / ijms17050626). [Prior art documents] [Patent documents]

[0022] [Patent Document 1] US Patent Application Publication No. 2013 / 0137644 [Patent Document 2] US Patent Application Publication No. 2004 / 0176282 [Patent Document 3] International Publication No. 2017 / 205846 [Non-patent literature]

[0023] [Non-Patent Document 1] Liang et al.,Biochem.Biophys.Res.Commun.;2005;335(3):734-738 [Non-Patent Document 2] Morris et al., Nature Biotechnol., 2001, 1173 - 1176 [Non - Patent Document 3] Perea et al., Cancer Res. 2004, 7127 - 7129 [Non - Patent Document 4] Wender et al., Adv. Drug Deliv. Rev. 2008, 452 - 472 [Non - Patent Document 5] Wender et al., Drug Discov. Today Technol. 2012, e49 - e55 [Non - Patent Document 6] Collins et al., Proc. R. Soc. B. Vol. 282. No. 1821. The Royal Society, 2015 [Non - Patent Document 7] Ledford, H., Nature, 2015, 522, 7554; Zetsche et al., Cell, 2015, 163(3), 759 - 771 [Non - Patent Document 8] Swiech et al., Nat. Biotechnol., 2015, 33, 102 - 106 [Non - Patent Document 9] Li et al., Human Gene Therapy, 2015, 26(7), 452 - 462 [Non - Patent Document 10] Wang et al., Proceedings of the National Academy of Sciences, 2016, 113(11), 2868 - 2873 [Non - Patent Document 11] Analytical Biochemistry 345(2005)55 - 65 [Non - Patent Document 12] Int. J. Mol. Sci. 2016, 17, 626; doi:10.3390 / ijms17050626 [Disclosure of the Invention] [Problems to be Solved by the Invention]

[0024] There remains in the art improved or alternative efficient means to facilitate the transfer of gene editing machinery across various cell membranes. [Means for solving the problem]

[0025] (Summary of the invention) These and other features, aspects, and advantages of the present subject matter will become better understood with reference to the following description and appended claims. This Summary is provided to introduce a selection of concepts in a simplified form. This Summary is not intended to identify key features or essential features of the claimed subject matter, nor is it intended to be used to limit the scope of the claimed subject matter.

[0026] In a first aspect, the present invention provides a genome editing complex for modifying a target polynucleotide comprising a class of recombinant beta helical proteins linked to one or more molecules of a genome editing system, wherein the length of the beta helical protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm.

[0027] In a second aspect, the present invention provides a genome editing complex for modifying a target polynucleotide comprising a recombinant beta helix protein linked to a plasmid encoding one or more molecules of a genome editing system, wherein the length of the beta helix protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm.

[0028] In embodiments, the one or more molecules of the genome editing system are selected from the group consisting of: a. RNA-guided endonuclease and / or guide RNA (gRNA); b. zinc finger nuclease (ZFN), c. Transcription Activator-Like Effector Nucleases (TALEN®); d. DNA-guided endonuclease and / or guide DNA; e. homing endonucleases, f integrase.

[0029] Preferably, the genome editing system is CRISPR-Cas9.

[0030] In embodiments, the gRNA has a sequence complementary to a target sequence in a target polynucleotide.

[0031] In embodiments, the modification resulting from genome editing is an addition, deletion, or substitution of one or more nucleotides in the target polynucleotide.

[0032] In an embodiment, the β helix protein has a roughly rectangular tip shape with a length in the range of 5 nm to 25 nm and a width in the range of 1 nm to 5 nm.

[0033] In embodiments, the beta helix protein comprises one or more amino acid ladder structures selected from the group consisting of an arginine ladder, a lysine ladder, an asparagine ladder, an aspartic acid ladder, and a glutamic acid ladder.

[0034] In embodiments, the arginine ladder contains 10-20 arginine residues, the lysine ladder contains 10-30 lysine residues, the asparagine ladder contains 10-40 asparagine residues, the aspartic acid ladder contains 10-40 aspartic acid residues, and the glutamic acid ladder contains 10-40 glutamic acid residues.

[0035] In embodiments, the beta helix protein has a total charge of less than zero.

[0036] In an embodiment, the β helix protein has a total charge of −20 to −60.

[0037] In an embodiment, the beta helix protein has a stiffness parameter K(beta helix) of 0.2 to 12 N / m as measured by atomic force microscopy. 2It has a β helical structure having the following structure:

[0038] In an embodiment, the beta helix protein is a pentapeptide repeat protein.

[0039] In an embodiment, the beta helix protein comprises a tandem repeat pentapeptide having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5.

[0040] In embodiments, the beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof.

[0041] In embodiments, the recombinant beta helix protein is linked to one or more molecules or plasmids of the genome editing system by non-covalent interactions.

[0042] In embodiments, the non-covalent interactions are selected from the group including hydrogen bonds, electrostatic interactions, van der Waals interactions, hydrophobic interactions, or combinations thereof.

[0043] In embodiments, the recombinant beta helix protein is linked to one or more molecules or plasmids of the genome editing system via a linker molecule selected from the group consisting of polyethylene glycol (PEG), ethylenediamine, peptides, metal conjugates, drug-metal conjugates, DNA binding domains, nucleic acid insert molecules, and combinations thereof.

[0044] In embodiments, when the linker molecule is a peptide, the peptide comprises amino acids selected from the group consisting of aliphatic amino acids, aromatic amino acids, and combinations thereof.

[0045] In embodiments, the linker is linked to the recombinant beta helix protein by covalent bonds, non-covalent bonds, and combinations thereof.

[0046] In embodiments, the recombinant beta helix protein is linked to one or more molecules or plasmids of the genome editing system via an ester or amide bond.

[0047] In embodiments, the genome editing complex further comprises a signal sequence, which directs the genome editing complex to a particular cell or portion of a cell.

[0048] In embodiments, the signal sequence is selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17.

[0049] In embodiments, the genome editing complex further comprises a phosphatidylcholine molecule.

[0050] In embodiments, the genome editing complex transfers one or more molecules or plasmids of a genome editing system to a location selected from the group consisting of an organelle, a nucleus, and a P-cadherin-overexpressing breast cancer cell.

[0051] In embodiments, the genome editing complex is used for genome editing.

[0052] In a third aspect, the present invention provides a method of preparing a genome editing complex of the first aspect of the invention, comprising combining a cell permeability protein with one or more genome editing system molecules, thereby forming a genome editing complex.

[0053] In an embodiment of the third aspect of the present invention, the one or more genome editing system molecules are in a reaction buffer that contains a molecule that stabilizes the complex formation between the cell permeable protein and the genome editing system. The reaction buffer can be selected based on ionic strength to optimize the electrostatic interactions between the various components of the complex. The ionic strength can be changed by the selection of components in the buffer, such as sodium chloride (NaCl).

[0054] Alternatively, in a fourth aspect, the present invention provides a method for preparing the genome editing complex of the second aspect of the invention, comprising combining a cell permeable protein with a plasmid, thereby forming a genome editing complex.

[0055] In a fifth aspect, the present invention provides a process for transferring one or more molecules of a genome editing system into a cell, the process comprising: a) linking one or more molecules of a genome editing system to a recombinant beta helix protein to obtain a conjugate or genome editing complex; b) contacting the conjugate or genome editing complex with at least one cell; The contacting of the conjugate or genome editing complex of step (b) transfers one or more molecules of the genome editing system into the cell, and the length of the beta helix protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm. Preferably, the process includes detecting the transfer of the genome editing complex in the cell after step (b).

[0056] In a sixth aspect, the present invention provides a process for transferring one or more molecules of a genome editing system into a cell, the process comprising: d) ligating the plasmid to a recombinant beta helix protein to obtain a conjugate or genome editing complex; e) contacting the conjugate or genome editing complex with at least one cell; The contacting of the conjugate or genome editing complex of step (d) transfers the plasmid into the cell, and the length of the beta helix protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm. Preferably, the process includes detecting transfer of the genome editing complex in the cell after step (d).

[0057] In an embodiment of the fifth and sixth aspects, the one or more molecules of the genome editing system are selected from the group consisting of: a. RNA-guided endonuclease and / or guide RNA (gRNA); b. zinc finger nuclease (ZFN), c. Transcription Activator-Like Effector Nucleases (TALEN®); d. DNA-guided endonuclease and / or guide DNA; e. homing endonucleases, f integrase.

[0058] In embodiments, the genome editing system is CRISPR-Cas9.

[0059] In embodiments, the gRNA has a sequence complementary to a target sequence in a target polynucleotide.

[0060] In embodiments, the modification resulting from genome editing is an addition, deletion, or substitution of one or more nucleotides in the target polynucleotide.

[0061] In an embodiment, in step a), linking one or more molecules of the genome editing system to a recombinant beta-helix protein to obtain a genome editing complex is performed in a reaction buffer containing a molecule that stabilizes complex formation between the recombinant beta-helix protein and one or more molecules of the genome editing system, and / or introduction of one or more molecules of the genome editing system into a cell is performed in a serum-free medium.

[0062] In an embodiment, the β helix protein has a roughly rectangular tip shape with a length in the range of 5 nm to 25 nm and a width in the range of 1 nm to 5 nm.

[0063] In embodiments, the beta helix protein comprises one or more amino acid ladder structures selected from the group consisting of an arginine ladder, a lysine ladder, an asparagine ladder, an aspartic acid ladder, and a glutamic acid ladder.

[0064] In embodiments, if present, the arginine ladder contains 10-20 arginine residues, the lysine ladder contains 10-30 lysine residues, the asparagine ladder contains 10-40 asparagine residues, the aspartic acid ladder contains 10-40 aspartic acid residues, and the glutamic acid ladder contains 10-40 glutamic acid residues.

[0065] In embodiments, the beta helix protein has a total charge of less than zero.

[0066] In an embodiment, the β helix protein has a total charge of −20 to −60.

[0067] In an embodiment, the beta helix protein has a strength of 0.2 to 12 N / m as measured by atomic force microscopy. 2 It has a β-helical structure (beta helix) with a stiffness parameter K of

[0068] In an embodiment, the beta helix protein is a pentapeptide repeat protein.

[0069] In an embodiment, the beta helix protein comprises a tandem repeat pentapeptide having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5.

[0070] In embodiments, the beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof.

[0071] In an embodiment, the genome editing complex is a genome editing complex of the first or second aspect of the invention.

[0072] In embodiments, the cell is selected from the group consisting of a eukaryotic cell, a prokaryotic cell, and combinations thereof.

[0073] In embodiments, the eukaryotic cell is a mammalian cell, a bacterial cell, a yeast cell, a plant cell, an insect cell, or a fish cell.

[0074] In a seventh aspect, the present invention provides a method of modifying a target polynucleotide in a cell comprising contacting the cell with a genome editing complex of the first or second aspect, wherein the genome editing complex targets a sequence in the target polynucleotide.

[0075] In an eighth aspect, the present invention provides a pharmaceutical composition comprising a genome editing complex of the first or second aspect of the present invention.

[0076] In a ninth aspect, the present invention provides a method of treating a disease in an individual comprising administering to the individual an effective amount of a pharmaceutical composition according to the seventh aspect of the invention.

[0077] In a tenth aspect, the present invention provides the use of a genome editing complex of the first or second aspect of the present invention for gene editing.

[0078] In an eleventh aspect, the present invention provides the use of a genome editing complex of the first or second aspect of the present invention for gene therapy.

[0079] Also disclosed herein is a cell-permeable conjugate comprising at least one recombinant β-helical protein molecule linked to a functional molecule, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm.

[0080] Further disclosed is a process for transferring a functional molecule into a cell, the process comprising: (a) linking a functional molecule to a recombinant β-helical protein to obtain a conjugate; (b) contacting the cell-permeable conjugate with at least one cell, wherein contacting the conjugate with the at least one cell transfers the nucleic acid molecule into the cell, and the β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm.

[0081] Also disclosed herein is the use of the cell-permeable conjugate of the first aspect of the present invention for delivering a functional molecule to a cell, wherein the functional molecule is selected from the group consisting of a dye, a drug, a metal, a drug-metal, a protein, an enzyme, an antibody, a nucleic acid, a polysaccharide, a nuclear localization signal, a nanoparticle, and combinations thereof.

[0082] Further disclosed herein is the use of the cell-permeable conjugate of the first aspect of the invention for cell penetration.

[0083] Further disclosed herein is the use of the cell-permeable conjugate of the first aspect of the invention for cell labeling.

[0084] Also disclosed herein is a conjugate comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm.

[0085] Further disclosed herein is a process for transferring a nucleic acid molecule into a cell, the process comprising: (i) linking the nucleic acid molecule to at least one recombinant β-helical protein via at least one linker to obtain a conjugate; and (ii) contacting the conjugate with at least one cell, wherein contacting the conjugate with the at least one cell transfers the nucleic acid molecule into the cell, and the recombinant β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm.

[0086] Further disclosed herein is the use of the cell-permeable conjugate of the sixth aspect of the invention as a transfection agent.

[0087] Further disclosed herein is the use of the cell-permeable conjugate of the sixth aspect of the invention for gene therapy. [Brief description of the drawings]

[0088] The following drawings form part of the present specification and are included to further explain aspects of the present disclosure. The present disclosure may be better understood by reference to the drawings in combination with the detailed description of specific embodiments presented herein. [Figure 1] 1 shows a CD (circular dichroism) spectrum of isolated AlbG protein according to the present disclosure. [Diagram 2] 1 shows an agarose gel containing purified plasmid (containing AlbG and EfsQNR genes) according to the present disclosure. [Diagram 3] 1 shows a polyacrylamide gel containing purified proteins (AlbG and EfsQNR) according to the present disclosure. [Figure 4] 1 shows MALDI-TOF mass spectral analysis of EfsQNR and AlbG proteins. [Diagram 5]1 shows a graphical representation of the characterization of labeled proteins (AlbG-NHSC and EfsQNR-NHSC) by UV-visible spectrophotometry, according to one embodiment of the present disclosure. [Figure 6] 1 shows differential labeling of HeLa cells with labeling proteins (conjugates) AlbG-NHSC, EfsQNR-NHSC and TtCuA-NHSC according to an embodiment of the present disclosure. [Figure 7] 1 shows labeling of HeLa cells with EfsQNRs labeled with ATTO-520 (a commercially available green fluorescent dye) according to one embodiment of the present disclosure. [Figure 8] 1 shows labeling of HeLa cells with EfsQNRs labeled with ATTO-390 (a commercially available blue fluorescent dye) according to one embodiment of the present disclosure. [Figure 9] According to one embodiment of the present disclosure, labeling of microglial cells with EfsQNRs labeled with ATTO-520 (a commercially available green fluorescent dye) is shown (Panel A), and differential labeling of microglial cells with EfsQNRs labeled with ATTO-520 is shown (Panel B). [Figure 10] According to one embodiment of the present disclosure, labeling of keratinocyte cells with EfsQNRs labeled with ATTO-520 (a commercially available green fluorescent dye) is shown (Panel A), and differential labeling of keratinocyte cells with EfsQNRs labeled with ATTO-520 is shown (Panel B). [Figure 11] 1 shows labeling of SH-SY5Y cells with EfsQNRs labeled with ATTO-520 (a commercially available green fluorescent dye) according to one embodiment of the present disclosure. [Figure 12] 1 shows labeling of mouse ES cells with EfsQNR labeled with ATTO-520 (a commercially available green fluorescent dye) according to one embodiment of the present disclosure. [Figure 13] 1 shows labeling of E. coli cells with EfsQNRs labeled with ATTO-520 (a commercially available green fluorescent dye) according to one embodiment of the present disclosure. [Figure 14] 1 shows labeling of yeast (Kluveromyces) cells with EfsQNRs labeled with ATTO-520 (a commercially available green fluorescent dye) according to one embodiment of the present disclosure. [Figure 15A] Standard FACS sorting of HeLa cells treated with EfsQNR-ATTO-647N-labeled conjugate for 10 min (Panel B), 1 h (Panel C), and 3 h (Panel D) are shown compared to untreated cells (Panel A). [Figure 15B] Standard FACS sorting of HeLa cells treated with EfsQNR-ATTO-647N-labeled conjugate for 10 min (Panel B), 1 h (Panel C), and 3 h (Panel D) are shown compared to untreated cells (Panel A). [Figure 15C] Standard FACS sorting of HeLa cells treated with EfsQNR-ATTO-647N-labeled conjugate for 10 min (Panel B), 1 h (Panel C), and 3 h (Panel D) are shown compared to untreated cells (Panel A). [Figure 15D] Standard FACS sorting of HeLa cells treated with EfsQNR-ATTO-647N-labeled conjugate for 10 min (Panel B), 1 h (Panel C), and 3 h (Panel D) are shown compared to untreated cells (Panel A). [Figure 16] 1 shows the rate of cellular uptake of a drug as part of a conjugate according to one embodiment of the present disclosure compared to the unconjugated drug. [Figure 17] 1 shows the viability of cells (Hela and HepG2) following treatment with the chemotherapeutic drug Cisplatin® (labeled CYDD) as part of a conjugate with the protein EfsQNR according to one embodiment of the present disclosure, compared to the unconjugated drug. [Figure 18] 1 shows a plasmid vector carrying the mcherry gene according to one embodiment of the present disclosure. [Figure 19] 1 shows a process for preparing a conjugate according to one embodiment of the present disclosure. [Figure 20] 1 shows a representation of transfection using a conjugate according to one embodiment of the present disclosure. [Figure 21]1 shows a confocal microscopy image of HeLa cells after transfection with a conjugate according to the invention, which contains the mcherry gene encoding RFP (red fluorescent protein) linked to the EfsQNR protein via copper[II]phenanthroline. [Figure 22] 1 shows real-time direct penetration of cell membranes by EfsQNR-ATTO520 conjugates according to the present invention. [Diagram 23] 1 shows labeling of plant Arabidopsis cells with CPPs labeled with ATTO-520 (a commercially available green fluorescent dye) according to one embodiment of the present disclosure. [Diagram 23] 1 shows labeling of plant Arabidopsis cells with CPPs labeled with ATTO-520 (a commercially available green fluorescent dye) according to one embodiment of the present disclosure. [Figure 24] 1 shows labeling of plant Arabidopsis cells with A) CPPs labeled with ATTO-520 (a commercially available green fluorescent dye), B) CPPs labeled with ATTO-594 (a commercially available red fluorescent dye), and C) CPPs labeled with ATTO-390 (a commercially available blue fluorescent dye) according to one embodiment of the present disclosure. [Diagram 25] 1 shows labeling of yeast cells with CPPs labeled with ATTO-520 (a commercially available green fluorescent dye) according to one embodiment of the present disclosure. [Figure 26] FIG. 1 shows the labeling of bacterial cells with CPPs labeled with ATTO-520 (a commercially available green fluorescent dye) according to one embodiment of the present disclosure. [Figure 27] 1 shows labeling of Drosophila embryonic cells with CPPs labeled with ATTO-520 (a commercially available green fluorescent dye), according to one embodiment of the present disclosure. [Figure 28] 1 shows labeling of zebrafish embryonic cells with CPPs labeled with ATTO-520 (a commercially available green fluorescent dye), according to one embodiment of the present disclosure. [Figure 29]Figure 2 shows the results of gene editing of HEK293 cells expressing eGFP after CPP-assisted delivery of CRISPR-Cas9 and eGFP-specific gRNA, as observed by a decrease in fluorescence intensity due to eGFP (measured with a fluorescent plate reader). [Diagram 30] (A) Transfection results in MCF7 cells using the conjugate (EfsQNR) (SEQ ID NO: 2) obtained in Example 1 and a 2.7 kb red-labeled circular plasmid DNA commercially available from Mirus Bio (product code MIR 7904), and (B) the control red-labeled plasmid used above in the absence of the conjugate: (i) shows the maximum projection of the cells after incubation, (ii) is the image corresponding to the intensity plot of the cells after incubation, and (iii) shows the intensity plot of the cells after incubation. [Diagram 31] 1 shows the results of a transfection experiment in MCF-7 cells using the conjugate (EfsQNR) obtained in Example 1 and the endonuclease Cas9 tagged with either (i) red fluorescent protein or (ii) green fluorescent dye Atto520. (A) shows the maximum projection of the cells after incubation, (B) shows the intensity plot of the cells after incubation, and (C) shows the 3D depth image of the cells. [Diagram 32] (A) shows the results of a transfection experiment in MCF-7 cells using the conjugate (EfsQNR) obtained in Example 1 and gRNA tagged with the green fluorescent dye MFP488, and (B) a control gRNA tagged with the green fluorescent dye MFP488. (i) shows a maximum projection of the cells after incubation, (ii) shows a 3D depth image of the cells, (iii) is an image corresponding to the intensity plot of the cells after incubation, and (iv) shows the intensity plot of the cells after incubation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0089] Those skilled in the art will recognize that the present disclosure is subject to changes and modifications other than those specifically described. It is to be understood that the present disclosure includes all such changes and modifications. The present disclosure also includes all such steps, features, compositions, and compounds individually or collectively referred to or shown in this specification, and any and all combinations of any or more of such steps or features.

[0090] definition For convenience, before further description of the present disclosure, certain terms and examples used herein are described here.These definitions should be read in light of the remainder of the present disclosure and understood by those skilled in the art.Terms used herein have meanings that are recognized and known to those skilled in the art, but for convenience and completeness, certain terms and their meanings are provided below.

[0091] Unless otherwise indicated, the practice of the present invention employs conventional techniques of chemistry, molecular biology, microbiology, recombinant DNA technology and chemical methods, which are within the capabilities of those of ordinary skill in the art. Such techniques are described, for example, in M. R. Green, J. Sambrook, 2012, Molecular Cloning: A Laboratory Manual, Fourth Edition, Books 1-3, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel, F. M. et al. (1995 and periodic supplements; Current Protocols in Molecular Biology, ch. 9, 13, and 16, John Wiley & Sons, New York, NY); B. Roe, J. Crabtree, and A. Kahn, 1996, DNA Isolation and Sequencing: Essential Techniques, John Wiley & Sons; J. M. Polak and James O'D. McGee, 1990, In Situ Hybridisation: Principles and Practice, Oxford University Press; M. J. Gait (Editor), 1984, Oligonucleotide Synthesis: A Practical Approach, IRL Press, and D. M. Lilley and and in J. E. Ahlberg, 1992, Methods of Enzymology: DNA Structure Part A: Synthesis and Physical Analysis of DNA Methods in Enzymology, Academic Press, each of which is incorporated herein by reference.

[0092] The articles "a", "an", and "the" are used to refer to one or to more than one (i.e. to at least one) of the grammatical object of the article.

[0093] As used herein, the term "comprising" means that any of the specified elements are necessarily included, and other elements may optionally be included as well. "Consisting essentially of" means that any specified elements are necessarily included, and that elements that materially affect the basic and novel characteristics of the recited elements are excluded, and other elements may optionally be included. "Consisting of" means that all elements other than the recited elements are excluded. Embodiments defined by each of these terms are within the scope of the present invention.

[0094] The term "including" is used to mean "including but not limited to." "Including" and "including but not limited to" are used interchangeably.

[0095] As used herein, the term "cell membrane" refers to a biological membrane that exists in both prokaryotic and eukaryotic cells and separates the cell's internal and external environments. It acts as a semi-permeable barrier that checks the transport of materials into and out of the cell and is typically formed from a phospholipid bilayer. The membrane acts as a support and helps maintain the shape and structure of the cell.

[0096] As used herein, the term "β-helical protein" refers to a protein that forms a β-helical secondary structure. β-helical proteins are formed from generally parallel pairing between adjacent β-strands of a peptide chain. β-helical proteins can be right-handed or left-handed β-helices, depending on the direction of coiling of the helical structure.

[0097] As used herein, the term "pentapeptide repeat protein (PRP)" refers to a beta-helical protein consisting of tandemly repeated pentapeptides. In embodiments, the tandemly repeated pentapeptides have the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5. The PRP family has well over 500 members in the prokaryotic and eukaryotic kingdoms.

[0098] As used herein, the term "functional molecule" is any molecule that has a utility within a cell. Examples of functional molecules suitable for use in the present invention include dyes, drug molecules, proteins, enzymes, antibodies, and nucleic acids.

[0099] As used herein, the term "cell penetrating peptide" or "CPP" refers to peptide sequences that facilitate cellular uptake / incorporation of various functional molecules. Cell penetrating peptides generally deliver functional molecules directly through the cell membrane, avoiding the need for endocytosis-mediated pathways for cell entry.

[0100] As used herein, the term "P-cadherin" refers to an intercellular adhesion molecule that has homeostatic function in normal tissues. Overexpression of this molecule is associated with significant tumor-promoting effects in neoplasms of the breast, ovary, prostate, endometrium, skin, stomach, pancreas, and colon.

[0101] As used herein, the term "NHS-coumarin" or "NHSC" refers to a fluorescent dye that is widely used in cell biology techniques. It is the common name for 7-(diethylamino)coumarin-3-carboxylic acid N-succinimidyl ester with a molecular weight of 358.35 g / mol. NHS-coumarin (NHSC) has an excitation wavelength of 445 nm and an emission wavelength of 482 nm. When observed under a fluorescence microscope, it emits green fluorescence, indicating the location and quantification of molecules conjugated with the dye.

[0102] As used herein, the term "phosphatidylcholine" defines a class of phospholipid molecules that incorporate choline as a head group. Phosphatidylcholines can be used as signaling molecules that promote selective binding and attachment to cell membranes.

[0103] As used herein, the term "Hoechst 33342" refers to a solution of a fluorescent dye used for both fixing DNA and nuclei and for live cell staining in cell imaging techniques. Hoechst 33342 is a cell-permeable DNA stain with an excitation wavelength of 460 nm, an emission wavelength of 490 nm, and binds preferentially to adenine (A)-thymine (T) regions of DNA.

[0104] As used herein, the terms "ATTO 520" or "A-520", "ATTO 390" or "A-390" and "ATTO 647N" or "A-647N" refer to fluorescent dyes developed by ATTO-Tec GmbH and commercially available from Sigma Aldrich, respectively.

[0105] As used herein, the term "ruthenium metal complex" refers to a coordination complex of ruthenium metal that is known to have anticancer activity. Octahedral ruthenium (III) and ruthenium (II) complexes show anti-neoplastic activity against many experimental tumors. Ruthenium metal complexes are considered a good alternative to avoid the side effects of platinum-based compounds. A non-limiting example of a ruthenium metal complex that has been demonstrated to be used in the present invention is tricarbonyldichlororuthenium (II) (e.g., Sigma Aldrich).

[0106] As used herein, the term "nucleic acid" refers to a single- or double-stranded covalently linked sequence of nucleotides with the 3' and 5' ends of each nucleotide joined by a phosphodiester bond. A polynucleotide may be composed of deoxyribonucleotide or ribonucleotide bases. Nucleic acids can include DNA and RNA, and are typically produced synthetically, but may also be isolated from natural sources. Nucleic acids may further include modified DNA or RNA, such as methylated DNA or RNA, or DNA or RNA that has been chemically modified, such as 5' capping with 7-methylguanosine, 3' processing such as cleavage and polyadenylation, and splicing, or labeling with fluorophores or other compounds. Nucleic acids may also include synthetic nucleic acids (XNA), such as hexitol nucleic acid (HNA), cyclohexene nucleic acid (CeNA), threose nucleic acid (TNA), glycerol nucleic acid (GNA), locked nucleic acid (LNA), and peptide nucleic acid (PNA). Therefore, when the terms "DNA" and "RNA" are used herein, it should be understood that these terms are not limited to include only naturally occurring nucleotides. The size of a nucleic acid, also referred to herein as a "polynucleotide", is typically expressed as the number of base pairs (bp) for double-stranded polynucleotides, or the number of nucleotides (nt) for single-stranded polynucleotides. 1000 bp or nt is equal to 1 kilobase (kb). Polynucleotides less than about 100 nucleotides in length are typically referred to as "oligonucleotides".

[0107] As used herein, the terms "3" ("three prime") and "5" ("five prime") have their ordinary meaning in the art, i.e., to distinguish the ends of a polynucleotide. Polynucleotides have 5' and 3' ends, and polynucleotide sequences are typically written in the 5' to 3' direction.

[0108] The term "amino acid" in the context of the present invention is used in its broadest sense and is meant to include naturally occurring Lα-amino acids or residues. In this specification, the one-letter and three-letter abbreviations commonly used for naturally occurring amino acids are used: A=Ala, C=Cys, D=Asp, E=Glu, F=Phe, G=Gly, H=His, I=Ile, K=Lys, L=Leu, M=Met, N=Asn, P=Pro, Q=Gln, R=Arg, S=Ser, T=Thr, V=Val, W=Trp, and Y=Tyr (Lehninger, AL, (1975) Biochemistry, 2d ed., pp. 71-92, Worth Publishers, New York). The general term "amino acid" further includes D-amino acids, retro-inverso amino acids, and chemically modified amino acids such as amino acid analogs, naturally occurring amino acids that are not normally incorporated into proteins such as norleucine, and chemically synthesized compounds that have the characteristic properties of amino acids such as β-amino acids. For example, analogs or mimetics of phenylalanine or proline allow the same conformational restrictions of peptide compounds as natural Phe or Pro, and are included in the definition of amino acid. Such analogs and mimetics are referred to herein as "functional equivalents" of the respective amino acids. Other examples of amino acids are listed by Roberts and Vellaccio, The Peptides: Analysis, Synthesis, Biology, Gross and Meiehofer, eds., Vol. 5 p. 341, Academic Press, Inc., NY 1983, which is incorporated herein by reference.

[0109] A "polypeptide" is a polymer of amino acid residues joined by peptide bonds, whether produced naturally or in vitro by synthetic means. Polypeptides less than about 12 amino acid residues in length are typically referred to as "peptides," and polypeptides from about 12 to about 30 amino acid residues in length may be referred to as "oligopeptides." As used herein, the term "polypeptide" refers to a naturally occurring polypeptide, a precursor form, or a product of a proprotein. Polypeptides may also undergo maturation or post-translational modification processes, which may include, but are not limited to, glycosylation, proteolytic cleavage, lipidation, signal peptide cleavage, propeptide cleavage, phosphorylation, and the like. The term "protein" is used herein to refer to a macromolecule comprising one or more polypeptide chains.

[0110] The term "isolated" when applied to a polynucleotide or protein sequence means that the sequence is removed from the natural organism in which it originates, and thus does not contain any foreign or undesired coding or regulatory sequences. Isolated sequences are suitable for use in the assembly of compositions and nanostructures of the invention. Such isolated sequences can include cDNA and RNA.

[0111] According to the present invention, homology to the nucleic acid or protein sequences described herein is not limited solely to 100% sequence identity. Nucleic acid or protein sequences closely related to those identified herein that exhibit functional and / or biochemical equivalence are considered to be within the scope of the present invention as defined by the claims.

[0112] The term "signal sequence" in the context of the present invention refers to nuclear localization sequences or recognition sequences of different organelles or nucleic acid binding domains such as zinc finger binding proteins.

[0113] As used herein, the term "carrier" means a substance that serves as a mechanism for improving the delivery and effectiveness of a drug.

[0114] As used herein, the term "diluent" (also called a filler, diluent, or thinner) means a diluent.

[0115] As used herein, the term "excipient" refers to an inert substance that acts as a vehicle or medium for a drug or other active substance. Excipients include colorants, moisturizers, preservatives, emollients, and combinations thereof.

[0116] As used herein, the term "RNA-guided endonuclease" refers to a polypeptide whose endonuclease activity and specificity depend on binding to at least one guide RNA molecule. An example of an RNA-guided endonuclease is Cas9 as part of the Cas9 / CRISPR system.

[0117] As used herein, the term "CRISPR" (clustered regularly interspaced short palindromic repeats) refers to a family of DNA sequences found in the genomes of prokaryotes, such as bacteria. The term may also be used to refer to a technique of gene editing that relies on the use of CRISPR-associated proteins, such as Cas-9 (CRISPR-associated protein 9), which can bind to and use the CRISPR sequence as a guide to recognize and cut specific strands of DNA that are complementary to the CRISPR sequence. Cas9 nuclease, together with the CRISPR sequence, forms the basis of the CRISPR-Cas9 gene editing technique.

[0118] As used herein, the term "Cas9" refers to the Cas9 endonuclease protein. Cas9, also called Csn1 (COG3513), is a large protein involved in both the biogenesis of crRNA and the destruction of invading DNA. The term "Cas9" is also meant to encompass engineered endonucleases or homologues of Cas9 that can process target nucleic acid sequences. Cas9 can induce cleavage of nucleic acid target sequences that can correspond to either double-stranded or single-stranded breaks. The term Cas9 is intended to include variants of the Cas9 endonuclease that do not naturally occur in nature and that are obtained by protein engineering or random mutagenesis, provided that such Cas9 variants remain functional, i.e., retain the ability to process target nucleic acid sequences.

[0119] As used herein, the term "CRISPR-RNP" refers to the CRISPR ribonucleotides that comprise CRISPR endonuclease protein and one or more guide RNAs. As used herein, the term "CRISPR-RNP-CPP" refers to the conjugate of the CRISPR-RNP complex with the cell-penetrating peptide of the present invention embodiment.

[0120] As used herein, the term "guide RNA" or "gRNA" refers to an RNA polynucleotide sequence that comprises a guide sequence. In use, the guide RNA can be associated with an endonuclease that acts to cut double-stranded DNA at the site determined by the gRNA. The term "guide sequence" refers to a sequence that has the ability to specify a target sequence in a genome, preferably longer than 8 nucleobases, more preferably longer than 10 nucleobases, and even more preferably longer than 12 nucleobases. In general, this RNA molecule has the ability to hybridize to the target sequence and mediate the endonuclease activity of the endonuclease.

[0121] As used herein, the term "wild-type" refers to the typical or naturally occurring form of an organism, strain, gene or overall characteristic, as distinguished from "mutant" or "variant" forms.

[0122] As used herein, the terms "non-naturally occurring" and "engineered" are used interchangeably. When referring to a nucleic acid molecule or polypeptide, the term means that the nucleic acid molecule or polypeptide is different from that found in nature and / or is at least substantially free from at least one other component with which it is naturally associated in nature.

[0123] As used herein, the term "complementarity" refers to the ability of a nucleic acid to bind to another nucleic acid sequence, either by non-covalent interactions, such as through hydrogen bonds, conventional Watson-Crick base pairing, or other non-conventional types. Complementarity percentage indicates the proportion of residues in a nucleic acid molecule that can form hydrogen bonds (Watson-Crick base pairs) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10, 50%, 60%, 70%, 80% / , 90%, and 100% complementary).

[0124] As used herein, the term "expression" refers to the process by which a polynucleotide is transcribed from a DNA template (e.g., into an mRNA or other RNA transcript) and / or the process by which the transcribed mRNA is subsequently translated into a peptide, polypeptide, or protein.

[0125] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this invention belongs.Although any method and material similar or equivalent to those described herein can be used in the practice or testing of this disclosure, the preferred method and material are described herein.All publications described herein are incorporated herein by reference.

[0126] array SEQ ID NO: 1 shows the amino acid sequence of the AlbG protein. MPAKTLESKDYCGESFVSEDRSGQSLESIRFEDCTFRQCNFTEAELNRCKFRECEFVDCNLSLISIPQTSFMEVRFVDCKMLGVNWTSAQWPSVKMEGALSFERCILNDSLFYGLYLAGVKMVECRIHDANFTEADCEDADFTQSDLKGSTFHNTKLTGASFIDAVNYHIDIFHNDIKRARFSLPEAASLLNSLDIELSD

[0127] SEQ ID NO: 2 shows the amino acid sequence of the EfsQNR protein. GSHMKITYPLPPNLPEQLPLLTNCQLEDEAILENHLYQQIDLPNQEVRNLVFRDAVFDHLSLANGQFASFDCSNVRFEACDFSNVEWLSGSFHRVTFLRCNLTGTNFADSYLKDCLFEDCKADYASFRFANFNLVHFNQTRLVESEFTESEVTWKKLLLEACDLNWLNTSLKGLDFSQNTFERLTFSPNYLSGLKVTPEQAIYLASALGLVIT

[0128] SEQ ID NO:3 shows the amino acid sequence of an antifreeze protein from Tenebrio molitor. QCTGGADCTSCTGACTGCGNCPNAVTCTNSQHCVKANTCTGSTDCNTAQTCTNSKDCFEANTCTDSTNCYKATACTNSSGCPGH

[0129] SEQ ID NO: 4 shows the amino acid sequence of an antifreeze protein from Rhagium inquisitor. GYSCRAVGVDGRAVTDIQGTCHAKATGAGAMASGTSEPGSTSTATATGRGATARSSTSTGRGTATTTATGTASATSNAIGQGTATTTATGSAGGRATGSATTSSSASQPTQTQTITGPGFQTAKSFARNTATTTVTASHHHHHH

[0130] SEQ ID NO:5 shows the amino acid sequence of an antifreeze protein from the Spruce Budworm (Choristoneura fumiferana). DGSCTNTNSQLSANSKCEKSTLTNCYVDKSEVYGTTCTGSRFDGVTITTSTSTGSRISGPGCKISTCIITGGVPAPSAACKISGCTFSAN

[0131] SEQ ID NO: 6 shows the amino acid sequence of the QNRB1 protein. GSHMALALVGEKIDRNRFTGEKIENSTFFNCDFSGADLSGTEFIGCQFYDRESQKGCNFSRAMLKDAIFKSCDLSMADFRNSSALGIEIRHCRAQGADFRGASFMMNMI TTRTWFCSAYITNTNLSYANFSKVVLEKCELWENRWIGAQVLGATFSSGSDLSGGEFSTFDWRAANFTHCDLTNSELGDLDIRGVDLQGVKLDNYQASLLMERLGIAVIG

[0132] SEQ ID NO: 7 shows the amino acid sequence of the UDP-N-acetylglucosamine acyltransferase protein. MIDKSAFVHPTAIVEEGASIGANAHIGPFCIVGPHVEIGEGTVLKSHVVVNGHTKIGRDNEIYQFASIGEVNQDLKYAGEPTRVEIGDRNRIRESVTIHRGTVQGGGLTKVGSDNLLMIN AHIAHDCTVGNRCILANNATLAGHVSVDDFAIIGGMTAVHQFCIIGAHVMVGGCSGVAQDVPPYVIAQGNHATPFGVNIEGLKRRGFSREAITAIRNAYKLIYRSGKTLDEVKPEIAELA ETYPEVKAFTDFFARSTRGLIR

[0133] SEQ ID NO: 8 shows the amino acid sequence of the NP275 protein from Nostoc punctiforme. MGSSHHHHHHSSGLVPRGSHMDVEKLRQLYAAGERDFSIVDLRGAVLENINLSGAILHGAMLDEANLQQANLSRADLSGATLNGADLRGANLSKADLSDAILDNAILEGAILDEAVLNQANLKAANLEQAILSHANIREADLSEANLEAADLSGADLAIA DLHQANLHQAALERANLTGANLEDANLEGTILEGGNNNLAT

[0134] SEQ ID NO: 9 shows the amino acid sequence of pectate lyase C. ATDTGGYAATAGGNVTGAVSKTATSMQDIVNIIDAARLDANGKKVKGGAYPLVITYTGNEDSLINAAAANICGQWSKDPRGVEIKEFTKGITIIGANGSSANFGIWIKKSSDVVVQNMRIGYLPGGAKDGDMIRVDDSPNVWVDHNELFAANHECDGTPD NDTTFESAVDIKGASNTVTVSYNYIHGVKKVGLDGSSSSDTGRNITYHHNYYNDVNARLPLQRGGLVHAYNNLYTNITGSGLNVRQNGQALIENNWFEKAINPVTSRYDGKNFGTWVLKGNNITKPADFSTYSITWTADTKPYVNADSWTSTGTFPTVAY NYSPVSAQCVKDKLPGYAGVGKNLATLTSTACK

[0135] SEQ ID NO: 10 shows the amino acid sequence of pectate lyase from Caldicellulosiruptor bescii. VGTNTGGVLVITDTIIVKSGQTYDGKGIKIIAQGMGDGSQSENQKPIFKLEKGANLKNVIIGAPGCDGIHCYGDNVVENVVWEDVGEDALTVKSEGVVEVIGGSAKEAADKVFQLNAPCTFKVKNFTATNIGKLVRQNGNTTFKVVIYLEDVTLNNVKSC VAKSDSPVSELWYHNLNVNNCKTLFEFPSQSQIHQY

[0136] SEQ ID NO: 11 shows the amino acid sequence of carbonic anhydrase from Methanosarcina thermophila. QEITVDEFSNIRENPVTWPNPEPSAPVIDPTAYIDPQASVIGEVTIGANVMVSPMASIRSDEGMPIFVGDRSNVQDGVVLHALETINEEGEPIEDNIVEVDGKEYA VYIGNNVSLAHQSQVHGPAAVGDDTFIGMQAFVFKSKVGNNCVLEPRSAAIGVTIPDGRYIPAGMVVTSQAEADKLPEVTDDYAYSHTNEAVVYVNVHLAEGYKETS

[0137] SEQ ID NO: 12 shows the amino acid sequence of the pectin lyase A protein from Aspergillus niger. VGVSGSAEGFAKGVTGGGSATPVYPDTIDELVSYLGDDEARVIVLTKTFDFTDSEGTTTGTGCAPWGTASACQVAIDQDDWCENYEPDAPSVSVEYYNAGTLGITVTSNKSLIGEGSSGAIKGKGLRIVSGAENIIIQNIAVTDINPKYVWGGDAITLDD CDLVWIDHVTTARIGRQHYVLGTSADNRVSLTNNYIDGVSDYSATCDGYHYWAIYLDGDADLVTMKGNYIYHTSGRSPKVQDNTLLHAVNNYWYDISGHAFEIGEGGYVLAEGNVFQNVDTVLETYEGEAFTVPSSTAGEVCSTYLGRDCVINGFGSSGT FSEDSTSFLSDFEGKNIASASAYTSVASRVVANAGQGNL

[0138] SEQ ID NO: 13 shows the amino acid sequence of the TtCuA protein. AYTLATHTAGVIPAGKLERVDPTTVRQEGPWADPAQAVVQTGPNQYTVYVLAFAFGYQPNPIEVPQGAEIVFKITSPDVIHGFHVEGTNINVEVLPGEVSTVRYTFKRPGEYRIICNQYCGLGHQNMFGTIVVKE

[0139] SEQ ID NO: 14 shows the signal sequence for targeting to the nucleus of the cell. PAAKRVKCD

[0140] SEQ ID NO: 15 shows a signal sequence for targeting to the endoplasmic reticulum of a cell. YPYDVPDYAKDEL

[0141] SEQ ID NO: 16 shows a signal sequence for targeting to the mitochondria of a cell. MLSLRQSIRFFKPATRTLCSSRYLL

[0142] SEQ ID NO:17 shows the signal sequence for targeting P-cadherin-overexpressing breast cancer cells. LSTAADMQGVVTDGMASGLDKDYLKPDD

[0143] SEQ ID NO: 18 shows the consensus sequence for pentapeptide repeat proteins. (STAV) 1 (DN) 2 (LF) 3 (STR) 4 (G) 5

[0144] SEQ ID NO: 19 shows the nucleic acid sequence of the AlbG gene. ATGCCGGCGAAAACCCTGGAAAGCAAAGATTATTGCGGCGAAAGCTTTGTGAGCGAAGATCGCAGCGGCCAGAGCCTGGAAAGCATTCGCCTTTGAAGATTGCACCTTTCGCCAGTGCAACTTTACCGGAAGCGGAACTGAACCGCTGCAAATTTCGCGAATGCGAATTTGTGGATTGCAACCTGAGCCTGATTAGCATTCCGCAGACCAGCTTTTATGGAAGTGCGCTTTGTGGATTGCAAAATGCTGGGCGTGAACTGGACCAGCCGCAGGCGGGCGCGCTGAGCTTTGAACGCTGCATT CTGAACGATAGCCTGTTTTATGGCCTGTATCTGGCGGGCGTGAAAATGGTGGAATGCCGCATTCATGATGCGAACTTTACCGAAGCGGATTGCGAAGATGCGGATTTTACCACAGAGCGATCTGAAAGGCAGCACCTTTCATAACACCAAACTGACCGGCGCGAGCTTTATTGATGCGGTGAACTATCATATTGATATTTTTCATAACGATATTAAACGCCGCGGCTTTAGCCTGCCGGAAGCGGCGAGCCTGCTGAACAGCCTGGATATTGAACTGAGCGA

[0145] Nucleic acid sequence 20 shows EfsQNR gene. GGCAGCCATATGAAAATTACCTATCCGCTGCCGCCGAACCTGCCGGAACAGCTGCCGCTGCTGACCAACTGCCAGCTGGAAGATGAAGCGATTCTGGAAAACCATCTGTATCAGCAGATTGATCTGCCGAACCAGGAAGTGCGCAACCTGGTGTTTCGCG ATGCGGTGTTTGATCATCTGAGCCTGGGCGAACGGCCAGTTTGCGAGCTTTGATTGCAGCAACGTGCGCTTTGAAGCGTGCGATTTTAGCAACGTGGAATGGCTGAGCGGCAGCTTTCATCGCGTGACCTTTCTGCGCTGCAACCTGACCGGCACCAACTTT GCGGATAGCTATCTGAAAGATTGCCTGTTTGAAGATTGCAAAGCGGATTATGCGAGCTTTCGCTTTGGCGAACTTTAACCTGGTGCATTTTAACCAGACCCGCCTGGTGGAAAGCGAATTTTTTGAAGTGACCTGGAAAAACTGCTGCTGGAAAGCGTGCGATCTGACCGAAAGCAACTGGCTGAACACCAGCCTGAAAGGCCTGGATTTTAGCCAGACACCTTTGAACGCCTGACCTTTAGCCCGAACTATCTGAGCGGCCTGAAAGTCCCGGAACAGGCGATTTATCTGCGGACGGCCTGGGCCTGGTGATTACC

[0146] Nucleic acid sequence of TtCuA gene is shown in sequence number 21. GCGTATACCCTGGCGACCCATACCGCGGGCGTGATTCCGGCGGGCAAACTGGAACGCGTGGATCCGACCACCGTGCGCCAGGAAGGCCCGTGGGCGGATCCGGCGCAGGCGGTGGTGCAGACCGGCCCGAACCAGTATACCGTGTATGTGCTGGCGTTTGCGTTTGGCTATCAGCCGAACCCGATTGAAGTGCCGCAGGGCG CGGAAATTGTGTTTAAAATTACCAGCCCGGATGTGATTCATGGCTTTCATGTGGAAGGCACCAACATTAACGTGGAAGTGCTGCCGGGCGAAGTGAGCACCGTGCGCTATACCTTTTAAACGCCCGGCGAATATCGCATTATTTGCAACCAGTATTGCGGCCTGGGCCATCAGAACATGTTTGGCACCATTGTGGTGAAAGAA

[0147] SEQ ID NO: 22 shows a signal sequence for targeting to intracellular actin. GDVQKKRWLFETKPLD

[0148] SEQ ID NO: 23 shows a signal sequence for targeting tubulin within the cell. VQSKCGSKDNIKHVPGGG

[0149] SEQ ID NO: 24: Shows the amino acid sequence of a zinc finger protein MERPYACPVESCDRRFSDSSNLTRHIRIHTGQKPFQCRICMRNFSRSDHLTTHIRTHTGEKPFACDICGRKFARSDERKR HTKIHLRQKD

[0150] SEQ ID NO: 25: Shows the nucleic acid sequence of the mcherry gene.

[0151] SEQ ID NO: 26: Shows the nucleic acid sequence of a primer for PCR amplification of the AlbG gene. ATCCCGCTCATATGCCGGCCAAGACCCTTG

[0152] SEQ ID NO: 27: Shows the nucleic acid sequence of a primer for PCR amplification of the AlbG gene. ATCCCGCTCTCGAGTCAATCGGACAGCTCGATATC

[0153] SEQ ID NO: 28: Shows the nucleic acid sequence of a primer for PCR amplification of the EfsQNR gene. ATCCCGCTCATATGAAAATAACTTATCCCTTGCCA

[0154] SEQ ID NO: 29: Shows the nucleic acid sequence of a primer for PCR amplification of the EfsQNR gene. ATCCCGCTCTCGAGTTAGGTAATCACCAAACCAAGT

[0155] The present invention also provides conjugates comprising recombinant proteins and functional molecules for permeabilizing cell membranes, and their uses having substantially similar sequence identity or homology to those of SEQ ID NOs: 1-12. The term "substantially similar sequence identity" is used herein to indicate a level of sequence similarity of about 50%, 60%, 70%, 80%, 90%, 95% to about 99% identity. Percent sequence identity can be determined using conventional methods, such as those described in Henikoff and Henikoff Proc. Natl. Acad. Sci. USA 1992;89:10915, and Altschul et al. Nucleic Acids Res. 1997;25:3389-3402 for nucleic acids, and for proteins via comparison after alignment using systems such as BLAST®.

[0156] Cell-permeable conjugates bearing functional molecules Identifying new drugs to cure or prevent life-threatening diseases remains a very active field of research. Most of such drugs tend to have targets inside the cells, and to reach the target, they will have to cross a semi-permeable membrane, which is often neither easy nor efficient. Therefore, it remains desirable to develop novel mechanisms to penetrate the cell membrane. Meanwhile, scientific investigations and studies aimed at elucidating various cellular mechanisms also seek to find novel ways to penetrate the cell membrane that can help in labeling the cell and its various organelles. This would also be very useful in supplying the necessary materials inside the cells for scientific experiments. Most of the cell-permeable molecules described in recent reports are related to the endocytosis mechanism of cell entry.

[0157] To avoid the disadvantages of uptake of molecules by endocytosis, e.g., trapping and degradation of drugs in different types of endosomal compartments that eventually fuse with degradative compartments of the cell, such as lysosomes, cell membrane-permeable conjugates are disclosed herein, which can penetrate the cell membrane to gain access into the cell, and can also be used to deliver various cargoes, including dyes, drugs, proteins, enzymes, antibodies, and nucleic acids, inside the cells.

[0158] The present disclosure should not be limited in scope by the specific embodiments described herein, which are for the purpose of illustration only. Functionally equivalent products, compositions, and methods are clearly within the scope of the present disclosure, as described herein.

[0159] The present invention discloses a conjugate capable of penetrating cell membranes. The conjugate comprises a recombinant beta helix protein, or a recombinant beta helix protein portion, linked to a functional molecule, the protein having a longest dimension defined as its length in the range of 5 nm to 25 nm and a width or diameter defined as a dimension of the protein structure substantially perpendicular to its length in the range of 1 nm to 5 nm. The protein dimensions are defined as measured in the solid state (characterized by X-ray crystallography or atomic force microscopy) or in solution (dynamic light scattering measurements).

[0160] In embodiments of the invention, the protein structure of the conjugate may have a longest dimension or length of more than 5 nm, 7.5 nm, 10 nm, 11 nm, 12 nm, 13 nm, or 14 nm. In embodiments, the protein structure of the conjugate may have a longest dimension or length of less than 25 nm, 20 nm, 17.5 nm, 15 nm, 14 nm, 13 nm, 12 nm, or 11 nm. Preferably, the length is in the range of 5 nm to 25 nm, more preferably 10 nm to 15 nm, and even more preferably 11 nm to 14 nm or 12 nm to 13 nm. In embodiments, the protein structure of the conjugate may have a width or diameter, in a dimension substantially perpendicular to its length, of at least 1 nm, 1.1 nm, 1.2 nm, 1.3 nm, 1.4 nm, 1.5 nm, 1.6 nm, 1.7 nm, 1.8 nm, 1.9 nm, or 2.0 nm. In embodiments, the protein structure of the conjugate may have a longest dimension or length of less than 5.0 mm, 4.5 nm, 4.0 nm, 3.5 nm, 3.0 nm, 2.9 nm, 2.8 nm, 2.7 nm, 2.6 nm, 2.5 nm, 2.4 nm, 2.3 nm, 2.2 nm, 2.1 nm, or 2.0 nm. Preferably, the length is in the range of 1 nm to 5 nm, more preferably 1 nm to 3 nm, and even more preferably 1.5 nm to 2.5 nm. In one embodiment, the protein structure of the conjugate of the invention may have a tip shape that is generally quadrangular (four sides) in cross section along the longitudinal axis. Preferably, the shape is rectangular. Preferably, it is the tip or end of the protein structure that is quadrangular. The tip may be generally rectangular, i.e., it may not have exact right angle corners or may have some rounded corners. Suitably the tip has a length in the range of 5 nm to 25 nm and a width in the range of 1 nm to 5 nm, In embodiments the tip may have the dimensions defined for the protein conjugates above.

[0161] A surrogate or alternative definition of the physical size of the protein moiety of the conjugate of the invention is its β-helical structure in combination with its molecular weight. Definitions of the size of a protein based on its physical dimensions or on its molecular weight may be used interchangeably. In an embodiment of the invention, the molecular weight of the protein moiety may be at least 30 kDa. Suitably, the molecular weight of the protein moiety may be at least 35 kDa, 40 kDa, 45 kDa or 50 kDa. In an embodiment of the invention, the molecular weight of the protein moiety may be at most 100 kDa. Suitably, the molecular weight of the protein moiety may be at most 90 kDa, 80 kDa, 70 kDa, 60 kDa, 55 kDa or 50 kDa. Suitably, the molecular weight range of the protein moiety of the conjugate of the invention is in the range of 30-100 kDa, more suitably 40-60 kDa, even more suitably 48-55 kDa.

[0162] Without wishing to be bound by theory, it is hypothesized that the beneficial properties in cell penetration exhibited by the conjugates of the invention are due to the physical size of the protein moiety, defined by the dimensions or molecular weight as outlined above. A further characteristic of proteins is their rigidity, which mainly stems from their unusual β-helical secondary structure. Advantageously, the protein may be more rigid than the membrane to be penetrated. Typical cell membranes have a stiffness of 0.005-0.02 N / m, depending on the cell type. 2 (measured by atomic force microscopy, Hayashi, "Tensile Properties and Local Stiffness of Cells"; Mechanics of Biological Tissue, pp 137-152). Preferably, the protein of the present invention has a stiffness of 0.7 to 12 N / m 2 has a rigidity, or high stiffness parameter (K), typical of a β-helix (Keten et al., Cell Mol. Bioeng. 2009;2;66-74, which is incorporated herein by reference).

[0163] A further feature believed to influence the efficiency of cell penetration of the conjugates of the invention is the charge profile and arrangement of amino acids in the β-helical structure of the protein. Specifically, the presence of a "ladder" of charged lysine, arginine, asparagine, aspartic acid and / or glutamic acid in a β-helical protein structure promotes penetration of the cell membrane and the overall negative charge of the protein sequence.

[0164] The term "ladder" in reference to amino acid residues in a beta-helical protein structure is defined as the presence of positively charged (lysine, arginine and / or asparagine) and negatively charged residues (aspartic acid and / or glutamic acid) along the length of the surface of the protein.

[0165] Without wishing to be bound by theory, the presence of a charged "ladder" structure in the beta helical structure of the protein according to the invention may facilitate the interaction of the protein with lipid molecules of the cell membrane (e.g., the formation of hydrogen bonds with hydroxyl groups of the lipid molecules) and / or the initial attachment of the protein to the negatively charged cell membrane.

[0166] The overall negative charge of the proteins according to the invention due to the negatively charged residues promotes repulsion leading to angular motion of the protein, allowing the protein to stand upright on the membrane and pierce the membrane.

[0167] In an embodiment of the invention, the protein of the conjugate comprises a ladder of exposed alternating positively and negatively charged amino acid residues on its surface. In an embodiment, the protein comprises at least one of an arginine ladder (10-30 Arg residues), a lysine ladder (10-30 Lys residues), an asparagine ladder (10-40 Asn residues), an aspartic acid (10-40 Asp residues), and a glutamic acid (10-40 Glu residues).

[0168] In an embodiment of the invention, the total formal charge of the protein may be zero or it may be non-zero. Preferably, the total formal charge is non-zero, more preferably, the total formal charge is less than zero (negative). In an embodiment, the total formal charge of the protein is below -10 (i.e., more negative than -10). Preferably, the total formal charge of the protein is below -20, -25, -30, -35, -40, -45, or -50. More preferably, the total formal charge is below -20. In an embodiment, the total formal charge of the protein is above -80 (i.e., less negative than -80). Preferably, the total formal charge of the protein is above -70, -65, -60, -55, -50, -45, -40, -35, or -30. More preferably, the total formal charge is above -60. In an embodiment, the total formal charge of the protein is in the range of -10 to -80, more preferably in the range of -20 to -60.

[0169] The efficiency and mechanism of cell penetration can be modulated by optimizing the total formal charge of the conjugate by increasing the number of positively charged residues (e.g., arginine) along the surface of the protein, and the sequence can be mutated at the N-terminus with signaling sequences (SEQ ID NOs: 14, 15, 16 or 17 and / or phosphatidylcholine) to achieve organelle specificity or specificity for particular cancer cells.

[0170] In one embodiment, proteins of the conjugates of the invention suitable for direct cell penetration (ie, non-endocytosis) may have one or more of the following structural parameters: -0.2~12N / m 2 a beta helix having a stiffness parameter of -5nm~25nm length, -1nm to 5nm diameter -Molecular weight of 25KDa to 100KDa, -Alternating ladders of surface-exposed positively and negatively charged residues on the surface of the protein along its length: arginine ladders (10-30 Arg residues), lysine ladders (10-30 Lys residues), asparagine ladders (10-40 Asn residues), aspartic acid (10-40 Asp residues) and glutamic acid (10-40 Glu residues), -Total formal charge (-20~-60).

[0171] In embodiments of the invention, the linker between the β-helical protein and the functional molecule may be formed by a direct link between the β-helical protein and the functional molecule, for example, via an amide (or peptide) or ester covalent bond, or via metal coordination, or the linker may take the form of a linker molecule. Suitably, the link is by a covalent or non-covalent bond or interaction. When the linker is a linker molecule, the linker molecule may take any suitable form that reversibly connects the β-helical protein and the functional molecule. In some embodiments, the linker molecule may be selected from the group consisting of a peptide or protein, a PEG (polyethylene glycol) linker, an organic molecule, a metal conjugate, a drug-metal conjugate, a nucleic acid binding domain, and a nucleic acid intercalating molecule.

[0172] In one embodiment, the present invention discloses a conjugate having a recombinant beta helix protein with a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, wherein the beta helix protein has a specific sequence linked to a functional molecule. Preferably, the specific sequence is a pentapeptide repeat. In an embodiment, the consensus sequence of the recombinant beta helix protein linked to the functional molecule is (STAV)1(DN)2(LF)3(STR)4(G)5. Examples of pentapeptide repeat proteins are SEQ ID NOs: 1, 2, 6 and 8.

[0173] In an embodiment of the present disclosure, the recombinant beta helix protein is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

[0174] In an embodiment of the present invention, the functional molecule can be any organic molecule (anticancer drugs, antibiotics, NSAIDs, analgesics or any other drug molecules, fluorescent dyes, insecticides, pesticides, etc.), drug-metal complexes, metals, antibodies, proteins, polysaccharides, nucleic acids, peptides, nuclear localization signals, quantum dots and nanoparticles.

[0175] The conjugates can be used to import functional molecules into cells, which is facilitated by the ability of the conjugates to penetrate cell membranes. With appropriate localization signals associated with or integrated into the conjugate or the functional molecule, or both, the conjugates of the present invention can be used to target functional molecules to specific parts of the interior of a cell, for example, organelles present inside the cell.

[0176] In one embodiment, the present invention also discloses a process for transferring functional molecules into cells using the cell-permeable conjugates of the present invention. The disclosed process can further be used for cell labeling, cell penetration, and targeting any functional molecule to organelles.

[0177] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm.

[0178] In an embodiment of the present disclosure, there is provided a cell-penetrating conjugate as described herein, wherein the beta helix protein is a pentapeptide repeat protein.

[0179] In one embodiment of the present disclosure, there is provided a cell-penetrating conjugate as described herein, wherein the beta helix protein comprises a tandem repeat pentapeptide having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5.

[0180] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof.

[0181] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the beta helix protein is AlbG having the sequence set forth in SEQ ID NO:1.

[0182] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the beta helix protein is EfsQNR having the sequence set forth in SEQ ID NO:2.

[0183] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is an antifreeze protein having the sequence set forth in SEQ ID NO: 3.

[0184] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is an antifreeze protein having the sequence set forth in SEQ ID NO:4.

[0185] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is an antifreeze protein having the sequence set forth in SEQ ID NO:5.

[0186] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule, the β-helical protein having a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is QNRB1 having the sequence set forth in SEQ ID NO:6.

[0187] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is a UDP N-acetylglucosamine acyltransferase having the sequence set forth in SEQ ID NO:7.

[0188] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is NP275 having the sequence set forth in SEQ ID NO:8.

[0189] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is pectate lyase C having the sequence set forth in SEQ ID NO:9.

[0190] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is a pectate lyase having the sequence set forth in SEQ ID NO: 10.

[0191] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule, the β-helical protein having a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is a carbonic anhydrase having the sequence set forth in SEQ ID NO:11.

[0192] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is pectin lyase A having the sequence set forth in SEQ ID NO: 12.

[0193] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is selected from the group consisting of a dye, a drug, a metal, a drug-metal complex, a protein, an enzyme, an antibody, a nucleic acid, a polysaccharide, a nuclear localization signal, a nanoparticle, and combinations thereof.

[0194] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is a dye.

[0195] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is a drug.

[0196] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is a metal.

[0197] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is a drug-metal complex.

[0198] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is a protein.

[0199] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is an enzyme.

[0200] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is an antibody.

[0201] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is a nucleic acid.

[0202] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is a polysaccharide.

[0203] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is a nuclear localization signal.

[0204] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is a nanoparticle.

[0205] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is linked to the recombinant beta-helix protein by a covalent bond, a non-covalent bond, and a combination thereof.

[0206] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is covalently linked to the recombinant beta-helix protein.

[0207] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein the functional molecule is linked to the recombinant beta-helix protein by a non-covalent bond.

[0208] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule described herein, wherein the complex further comprises a signal sequence.

[0209] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta-helix protein linked to a functional molecule as described herein, the conjugate further comprising a phospholipid molecule.

[0210] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule as described herein, wherein the conjugate further comprises a signal sequence selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17.

[0211] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta-helix protein linked to a functional molecule as described herein, the conjugate further comprising a phosphatidylcholine molecule.

[0212] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule as described herein, wherein the conjugate further comprises a signal sequence as set forth in SEQ ID NO:14.

[0213] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule as described herein, wherein the conjugate further comprises a signal sequence as set forth in SEQ ID NO:15.

[0214] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule as described herein, wherein the conjugate further comprises a signal sequence as set forth in SEQ ID NO:16.

[0215] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule as described herein, wherein the conjugate further comprises a signal sequence as set forth in SEQ ID NO:17.

[0216] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule for importing the functional molecule into the nucleus of a cell, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the conjugate further comprises a signal sequence set forth in SEQ ID NO:14.

[0217] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule for importing the functional molecule described herein into the nucleus of a cell, wherein the beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof, and the conjugate further comprises a signal sequence set forth in SEQ ID NO:14.

[0218] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule for importing the functional molecule described herein into the nucleus of a cell, wherein the functional molecule is selected from the group consisting of a dye, a drug, a metal, a drug-metal complex, a protein, an enzyme, an antibody, a nucleic acid, a polysaccharide, a nuclear localization signal, a nanoparticle, and combinations thereof.

[0219] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule for importing the functional molecule into the endoplasmic reticulum of a cell, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the conjugate further comprises a signal sequence set forth in SEQ ID NO:15.

[0220] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule for importing the functional molecule described herein into the endoplasmic reticulum of a cell, wherein the beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof, and the conjugate further comprises a signal sequence as set forth in SEQ ID NO:15.

[0221] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta-helical protein linked to a functional molecule for importing the functional molecule described herein into the endoplasmic reticulum of a cell, wherein the functional molecule is selected from the group consisting of a dye, a drug, a metal, a drug-metal complex, a protein, an enzyme, an antibody, a nucleic acid, a polysaccharide, a nuclear localization signal, a nanoparticle, and combinations thereof.

[0222] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule for importing the functional molecule into the mitochondria of a cell, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the conjugate further comprises a signal sequence set forth in SEQ ID NO:16.

[0223] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule for importing the functional molecule described herein into the mitochondria of a cell, wherein the beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof, and wherein the conjugate further comprises a signal sequence set forth in SEQ ID NO:16.

[0224] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta-helical protein linked to a functional molecule for importing the functional molecule described herein into the mitochondria of a cell, wherein the functional molecule is selected from the group consisting of a dye, a drug, a metal, a drug-metal complex, a protein, an enzyme, an antibody, a nucleic acid, a polysaccharide, a nuclear localization signal, a nanoparticle, and combinations thereof.

[0225] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule for transferring the functional molecule into P-cadherin-overexpressing breast cancer cells, wherein the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the conjugate further comprises a signal sequence set forth in SEQ ID NO:17.

[0226] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule for transferring the functional molecule described herein into P-cadherin-overexpressing breast cancer cells, wherein the beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof, and the conjugate further comprises a signal sequence set forth in SEQ ID NO:17.

[0227] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule for the transfer of the functional molecule described herein to P-cadherin-overexpressing breast cancer cells, wherein the functional molecule is selected from the group consisting of a dye, a drug, a metal, a drug-metal complex, a protein, an enzyme, an antibody, a nucleic acid, a polysaccharide, a nuclear localization signal, a nanoparticle, and combinations thereof.

[0228] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant β-helical protein linked to a functional molecule for importing the functional molecule into the membrane of a cell, the β-helical protein having a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the conjugate further comprising a phosphatidylcholine molecule.

[0229] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta helix protein linked to a functional molecule for importing the functional molecule described herein into the membrane of a cell, wherein the beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof, and the conjugate further comprises a phosphatidylcholine molecule.

[0230] In one embodiment of the present disclosure, a cell-permeable conjugate is provided comprising a recombinant beta-helix protein as described herein linked to a functional molecule for importing the functional molecule into the membrane of a cell, wherein the functional molecule is selected from the group consisting of a dye, a drug, a metal, a drug-metal complex, a protein, an enzyme, an antibody, a nucleic acid, a polysaccharide, a nuclear localization signal, a nanoparticle, and combinations thereof.

[0231] In one embodiment of the present disclosure, a process for transferring a functional molecule into a cell is provided, the process comprising: (a) linking a functional molecule to a recombinant β-helical protein to obtain a conjugate; and (b) contacting the conjugate with at least one cell, wherein the contacting of the conjugate transfers the functional molecule into the cell, and the β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm. In one embodiment, the process further comprises, after step (c), detecting transfer of the conjugate in the cell in step (d).

[0232] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, wherein the beta helix protein is a pentapeptide repeat protein.

[0233] In one embodiment of the present disclosure, a process is provided for importing the functional molecules described herein into cells, wherein the beta helix protein comprises a tandem repeat pentapeptide having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5.

[0234] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, wherein the beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof.

[0235] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, wherein the beta helix protein is AlbG having the sequence set forth in SEQ ID NO:1.

[0236] In one embodiment of the present disclosure, a process for transferring the functional molecules described herein into cells is provided, wherein the β-helix protein is EfsQNR having the sequence set forth in SEQ ID NO:2.

[0237] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, wherein the beta helix protein is an antifreeze protein having the sequence set forth in SEQ ID NO:3.

[0238] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, wherein the beta helix protein is an antifreeze protein having the sequence set forth in SEQ ID NO:4.

[0239] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, wherein the beta helix protein is an antifreeze protein having the sequence set forth in SEQ ID NO:5.

[0240] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, wherein the beta helix protein is QNRB1 having the sequence set forth in SEQ ID NO:6.

[0241] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, wherein the beta helix protein is UDP N-acetylglucosamine acyltransferase having the sequence set forth in SEQ ID NO:7.

[0242] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, wherein the beta helix protein is NP275 having the sequence set forth in SEQ ID NO:8.

[0243] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, wherein the beta helix protein is pectate lyase C having the sequence set forth in SEQ ID NO:9.

[0244] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into a cell, wherein the beta helix protein is a pectate lyase having the sequence set forth in SEQ ID NO:10.

[0245] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, wherein the beta helix protein is carbonic anhydrase having the sequence set forth in SEQ ID NO:11.

[0246] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the beta helix protein has the sequence set forth in SEQ ID NO:12.

[0247] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the functional molecule is selected from the group consisting of a dye, a drug, a metal, a drug-metal complex, a protein, an enzyme, an antibody, a nucleic acid, a polysaccharide, a nuclear localization signal, a nanoparticle, and combinations thereof.

[0248] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the functional molecule is a dye.

[0249] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the functional molecule is a drug.

[0250] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the functional molecule is a metal.

[0251] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the functional molecule is a drug-metal complex.

[0252] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the functional molecule is a protein.

[0253] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the functional molecule is an enzyme.

[0254] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the functional molecule is an antibody.

[0255] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the functional molecule is a nucleic acid.

[0256] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the functional molecule is a polysaccharide.

[0257] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the functional molecule is a nuclear localization signal.

[0258] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the functional molecule is a nanoparticle.

[0259] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, wherein the functional molecules are linked to recombinant beta helix proteins by covalent bonds, non-covalent bonds, and combinations thereof.

[0260] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the cell is selected from the group consisting of a eukaryotic cell, a prokaryotic cell, and a combination thereof.

[0261] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the cell is a prokaryotic cell.

[0262] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the cell is a eukaryotic cell.

[0263] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the beta helix protein is represented by the sequence set forth in SEQ ID NO:1 and the functional molecule is an NHS-coumarin dye.

[0264] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the beta helix protein is represented by the sequence set forth in SEQ ID NO:2, and the functional molecule is an NHS-coumarin dye.

[0265] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cell, wherein the beta helix protein is represented by the sequence set forth in SEQ ID NO:2, and the functional molecule is a ruthenium metal complex.

[0266] In one embodiment of the present disclosure, a process is provided for transferring the functional molecules described herein into cells, which process is used for cell labeling.

[0267] In one embodiment of the present disclosure, a process for transferring the functional molecules described herein into cells is provided, which is used to deliver the functional molecules to cells.

[0268] In one embodiment of the present disclosure, a process for importing a functional molecule into a cellular organelle is provided, the process comprising: (a) linking a functional molecule to a recombinant β-helical protein to obtain a conjugate; (b) further incorporating any one signal sequence selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, and SEQ ID NO: 16 into the conjugate; and (c) contacting the conjugate of step (b) with at least one cell, wherein contacting the conjugate of step (b) imports the functional molecule into an organelle in the cell, the organelle being selected from the group consisting of the nucleus, the endoplasmic reticulum, and the mitochondria, and the length of the β-helical protein is in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and the width is in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm. In one embodiment, the process further comprises detecting the import of the conjugate in the cell in step (d) after step (c).

[0269] In one embodiment of the present disclosure, a process is provided for importing a functional molecule described herein into a cellular organelle, wherein the recombinant beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof.

[0270] In one embodiment of the present disclosure, a process is provided for importing a functional molecule described herein into the nucleus of a cell, wherein the signal sequence is as set forth in SEQ ID NO:14.

[0271] In one embodiment of the present disclosure, a process is provided for importing a functional molecule described herein into the endoplasmic reticulum of a cell, wherein the signal sequence is as set forth in SEQ ID NO:15.

[0272] In one embodiment of the present disclosure, a process is provided for importing a functional molecule described herein into the mitochondria of a cell, wherein the signal sequence is as set forth in SEQ ID NO: 16.

[0273] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into a cellular organelle, wherein the functional molecule is selected from the group consisting of a dye, a drug, a metal, a drug-metal complex, a protein, an enzyme, an antibody, a nucleic acid, a polysaccharide, a nuclear localization signal, a nanoparticle, and combinations thereof.

[0274] In one embodiment of the present disclosure, a process for transferring a functional molecule into P-cadherin-overexpressing breast cancer cells is provided, the process comprising: (a) linking the functional molecule to a recombinant β-helical protein to obtain a complex; (b) further incorporating a signal sequence set forth in SEQ ID NO: 17 into the complex; and (c) contacting the complex of step (b) with at least one P-cadherin-overexpressing breast cancer cell, wherein contacting the complex of step (b) transfers the functional molecule into the P-cadherin-overexpressing breast cancer cell, and the length of the β-helical protein is in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and the width is in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm. In one embodiment, the process further comprises detecting the transfer of the complex in the cell in step (d) after step (c).

[0275] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into P-cadherin-overexpressing breast cancer cells, wherein the recombinant beta helix protein having a sequence is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

[0276] In one embodiment of the present disclosure, a process is provided for transferring a functional molecule described herein into P-cadherin-overexpressing breast cancer cells, wherein the functional molecule is selected from the group consisting of a dye, a drug, a metal, a drug-metal complex, a protein, an enzyme, an antibody, a nucleic acid, a polysaccharide, a nuclear localization signal, a nanoparticle, and combinations thereof.

[0277] In one embodiment of the present disclosure, there is provided a process as described herein, which is used for targeted delivery of functional molecules to cells.

[0278] In one embodiment of the present disclosure, there is provided a process as described herein, which is used for labeling of cells.

[0279] In one embodiment of the present disclosure, there is provided a process as described herein, which is used for targeted delivery of a drug in a cell.

[0280] In one embodiment of the present disclosure, there is provided a cell-penetrating complex as described herein, wherein the recombinant beta helix protein is used to deliver a functional molecule to a cell, the functional molecule being selected from the group consisting of a dye, a drug, a metal, a drug-metal conjugate, a protein, an enzyme, an antibody, a nucleic acid, a polysaccharide, a nuclear localization signal, a nanoparticle, and combinations thereof.

[0281] In one embodiment of the present disclosure, a process for transferring a functional molecule into an actin protein present in a cell is provided, the process comprising: (a) linking a functional molecule to a recombinant β-helical protein to obtain a conjugate; (b) further incorporating a signal sequence set forth in SEQ ID NO: 22 into the complex; and (c) contacting the conjugate of step (b) with at least one cell, wherein contacting the conjugate of step (b) transfers the functional molecule into the cell, and the length of the β-helical protein is in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and the width is in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm. In one embodiment, the process further comprises, after step (c), detecting the transfer of the conjugate in the cell in step (d).

[0282] In one embodiment of the present disclosure, a process for transferring a functional molecule into a tubulin protein present in a cell is provided, the process comprising: (a) linking a functional molecule to a recombinant β-helical protein to obtain a conjugate; (b) further incorporating a signal sequence set forth in SEQ ID NO: 23 into the conjugate; and (c) contacting the conjugate of step (b) with at least one cell, wherein contacting the conjugate of step (b) transfers the functional molecule into a P-cadherin-overexpressing breast cancer cell, and the length of the β-helical protein is in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and the width is in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm. In one embodiment, the process further comprises detecting the transfer of the conjugate in the cell in step (d) after step (c).

[0283] In one embodiment of the present disclosure, there is provided a cell-penetrating conjugate as described herein, wherein a recombinant beta-helix protein is used for cell penetration.

[0284] In one embodiment of the present disclosure, there is provided a cell-permeable conjugate as described herein, wherein a recombinant beta-helix protein is used for cell labeling.

[0285] Cell-penetrating molecules containing nucleic acids In one embodiment, the present invention provides a solution to the problem of delivery of nucleic acid fragments as functional molecules faced in gene therapy or gene editing therapy. The present specification discloses a conjugate comprising a recombinant beta helix protein linked to a nucleic acid molecule, for example a plasmid, such as an RNA- or DNA-plasmid, capable of permeating cell membranes. In one embodiment, the linked recombinant beta helix protein can be linked to one or more nucleic acid molecules, preferably a single nucleic acid molecule or plasmid, by suitable interaction forces (such as electrostatic or hydrophobic forces) or via a linker element, molecule, portion or moiety.

[0286] A conjugate comprising a recombinant β-helical protein, a linker, and a plasmid has been shown to successfully penetrate the cell membrane and establish expression of the gene that forms part of the plasmid. The conjugate avoids the endocytic pathway and crosses the cell membrane by penetrating the cell membrane directly. Thus, the conjugate overcomes the problems faced by entry via endocytosis while at the same time effectively penetrating the cell membrane.

[0287] In one embodiment, the present invention discloses a conjugate capable of penetrating a cell membrane. In some embodiments, the conjugate comprises a recombinant beta helix protein with a length ranging from 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width ranging from 1 nm to 5 nm, preferably 1 nm to 3 nm, linked to a nucleic acid molecule via a linker. In one embodiment, the recombinant beta helix protein can be a pentapeptide repeat protein having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5. In another embodiment of the present disclosure, the recombinant beta helix protein is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

[0288] According to the present disclosure, in one embodiment, the recombinant beta helix protein is linked to the nucleic acid molecule by a linker element, molecule, moiety or portion. In an embodiment, the linker element can be a direct linkage by a covalent or non-covalent bond. When the linker is a linker molecule, it can be selected from the group consisting of a protein, a metal conjugate, a drug-metal conjugate, a DNA binding domain, and a nucleic acid insert molecule. In one embodiment, the nucleic acid molecule comprising part of the conjugate comprises at least one gene of interest. In one embodiment, the nucleic acid molecule is linked to a complex comprising the recombinant beta helix protein and a linker to form a conjugate as disclosed in the present invention. In one embodiment, the conjugate can enter the cell by penetrating the cell membrane, and the gene forming part of the nucleic acid molecule can be expressed in the cell.

[0289] The present invention also discloses the process of using the conjugate of the present invention to transfer nucleic acid molecule into cells.In one embodiment, the disclosed process can be further used in gene therapy or gene editing technology to facilitate the non-viral approach to deliver the gene of interest in cells, thereby effectively enabling defective gene editing or complementing defective gene or protein inside cells.

[0290] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β-helical protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm.

[0291] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and wherein the β helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof.

[0292] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and wherein the β helix protein is a pentapeptide repeat protein.

[0293] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and wherein the β helix protein comprises a tandem repeat pentapeptide having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5.

[0294] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β-helical protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the linker is a linker molecule selected from the group consisting of a protein, a metal conjugate, a drug-metal conjugate, a DNA binding domain, a nucleic acid intercalating molecule, and combinations thereof.

[0295] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β-helical protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm; the β-helical protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof; and the linker is a linker molecule selected from the group consisting of a protein, a metal conjugate, a drug-metal conjugate, a DNA binding domain, a nucleic acid insert molecule, and combinations thereof.

[0296] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the linker is linked to the recombinant β helix protein by a covalent bond, a non-covalent bond, or a combination thereof.

[0297] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm; and the linker is a linker molecule selected from the group consisting of a protein, a metal conjugate, a drug-metal conjugate, a DNA binding domain, a nucleic acid intercalating molecule, and combinations thereof, and the linker is linked to the recombinant β helix protein by a covalent bond, a non-covalent bond, and combinations thereof.

[0298] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β-helical protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the nucleic acid molecule comprises at least one gene of interest.

[0299] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β-helical protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and wherein the β-helical protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof, and wherein the nucleic acid molecule comprises at least one gene of interest.

[0300] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β-helical protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm; the β-helical protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof; the linker is a linker molecule selected from the group consisting of a protein, a metal conjugate, a drug-metal conjugate, a DNA binding domain, a nucleic acid insert molecule, and combinations thereof; and the nucleic acid molecule comprises at least one gene of interest.

[0301] In one embodiment, the present invention provides a solution to the problem of delivery of gene editing molecular machinery across a cell membrane and into a cell and / or its compartments by providing a means to transfect a cell with a plasmid or nucleic acid encoding one or more molecules of a genome editing system. Once the plasmid or nucleic acid is inside the cell, one or more molecules of the genome editing system within the cell can be prepared using cellular processes and optionally combined with other necessary components of the genome editing system to provide a complete gene editing system within the cell.

[0302] In one embodiment of the present disclosure, the gene of interest in nucleic acid or plasmid encodes one or more molecules of genome editing system.Preferably, the one or more molecules of genome editing system are selected from the group consisting of RNA-guided endonuclease and / or guide RNA (gRNA), such as Cas9, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN®), DNA-guided endonuclease and / or guide DNA, homing endonuclease, integrase, and any combination thereof, but are not limited thereto.

[0303] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β-helical protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is AlbG having the sequence set forth in SEQ ID NO:1.

[0304] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β-helical protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is EfsQNR having the sequence set forth in SEQ ID NO: 2.

[0305] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β helix protein is an antifreeze protein having the sequence set forth in SEQ ID NO: 3.

[0306] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β helix protein is an antifreeze protein having the sequence set forth in SEQ ID NO:4.

[0307] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β helix protein is an antifreeze protein having the sequence set forth in SEQ ID NO:5.

[0308] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β helix protein is QNRB1 having the sequence set forth in SEQ ID NO: 6.

[0309] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β helix protein is UDP N-acetylglucosamine acyltransferase having the sequence set forth in SEQ ID NO:7.

[0310] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β helix protein is NP275 having the sequence set forth in SEQ ID NO:8.

[0311] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β helix protein is pectate lyase C having the sequence set forth in SEQ ID NO: 9.

[0312] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β helix protein is a pectate lyase having the sequence set forth in SEQ ID NO: 10.

[0313] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β helix protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β helix protein is a carbonic anhydrase having the sequence set forth in SEQ ID NO:11.

[0314] In one embodiment of the present disclosure, a conjugate is provided comprising: (a) at least one recombinant β-helical protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the at least one recombinant β-helical protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm, and the β-helical protein is pectin lyase A having the sequence set forth in SEQ ID NO: 12.

[0315] In one embodiment of the present disclosure, a process for transferring a nucleic acid molecule or a plasmid into a cell is provided, the process comprising: (i) linking the nucleic acid molecule to a complex comprising (a) at least one recombinant β helix protein and (b) at least one linker to obtain a conjugate; and (ii) contacting the conjugate with at least one cell, wherein contacting the conjugate transfers the nucleic acid molecule into the cell, and the recombinant β helix protein has a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width in the range of 1 nm to 5 nm, preferably 1 nm to 3 nm.

[0316] In one embodiment of the present disclosure, a process is provided for transferring a nucleic acid molecule or plasmid described herein into a cell, wherein the beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof.

[0317] In one embodiment of the present disclosure, a process is provided for transferring a nucleic acid molecule described herein into a cell, wherein the beta helix protein is a pentapeptide repeat protein.

[0318] In one embodiment of the present disclosure, a process is provided for transferring the nucleic acid molecules described herein into cells, wherein the beta helix protein comprises a tandem repeat pentapeptide having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5.

[0319] In one embodiment of the present disclosure, a process is provided for transferring the nucleic acid molecules described herein into cells, wherein the linker is a linker molecule selected from the group consisting of a protein, a metal conjugate, a drug-metal conjugate, a DNA binding domain, a nucleic acid intercalating molecule, and combinations thereof.

[0320] In one embodiment of the present disclosure, a process is provided for transferring a nucleic acid molecule described herein into a cell, wherein the beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof, and the linker is a linker molecule selected from the group consisting of a protein, a metal conjugate, a drug-metal conjugate, a DNA binding domain, a nucleic acid intercalating molecule, and combinations thereof.

[0321] In one embodiment of the present disclosure, a process is provided for transferring the nucleic acid molecules described herein into a cell, wherein the linker is linked to the recombinant beta helix protein by covalent bonds, non-covalent bonds, and combinations thereof.

[0322] In one embodiment of the present disclosure, a process is provided for transferring the nucleic acid molecules described herein into cells, wherein the linker is a linker molecule selected from the group consisting of a protein, a metal conjugate, a drug-metal conjugate, a DNA binding domain, a nucleic acid intercalating molecule, and combinations thereof, and the linker is linked to the recombinant beta helix protein by a covalent bond, a non-covalent bond, and combinations thereof.

[0323] In one embodiment of the present disclosure, a process is provided for transferring a nucleic acid molecule described herein into a cell, the cell being either a prokaryotic or eukaryotic cell.

[0324] In one embodiment of the present disclosure, a process is provided for transferring the nucleic acid molecule described herein into cells, and the nucleic acid or gene of interest in a plasmid encodes one or more molecules of genome editing system.Preferably, the one or more molecules of genome editing system are selected from the group consisting of, but not limited to, RNA-guided endonuclease and / or guide RNA (gRNA), such as Cas9, zinc finger nuclease (ZFN), transcription activator-like effector nuclease (TALEN®), DNA-guided endonuclease and / or guide DNA, homing endonuclease, integrase, and any combination thereof.

[0325] Cell-penetrating peptides for efficient delivery of gene-editing molecules across cell membranes The present invention provides a solution to the problem of delivering gene editing molecular machinery to cells and / or its compartments across cell membranes.The present specification discloses a conjugate comprising a recombinant beta helix protein linked to at least one gene editing molecule or gene editing complex, which can efficiently penetrate cell membranes.In one embodiment, the recombinant beta helix protein can be linked to an endonuclease and one or more gRNA molecules by non-covalent interactions.In one embodiment, the recombinant beta helix protein can be linked to a CRISPR gene editing molecule, such as Cas9 endonuclease or gRNA, and / or a complex of Cas9 and one or more gRNA molecules by non-covalent interactions.

[0326] Conjugates comprising recombinant beta helix proteins and CRISPR gene editing molecules have been shown to successfully penetrate cell membranes, allowing site-specific editing of genomes.Without being bound by theory, it is hypothesized that the conjugates avoid the endocytic pathway and cross cell membranes by directly penetrating the membrane.Thus, the conjugates overcome the problems faced by endocytic entry, and at the same time effectively penetrate cell membranes.

[0327] In some embodiments, the conjugate comprises a recombinant beta helix protein with a length ranging from 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width ranging from 1 nm to 5 nm, preferably 1 nm to 3 nm, linked to a nucleic acid molecule via a linker. In one embodiment, the recombinant beta helix protein can be a pentapeptide repeat protein having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5. In another embodiment of the present disclosure, the recombinant beta helix protein is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12.

[0328] According to the present disclosure, in one embodiment, the recombinant beta helix protein is linked to the nucleic acid molecule by a linker element, molecule, part or moiety. In an embodiment, the linker element can be a direct linkage by covalent or non-covalent bond. When the linker is a linker molecule, it can be selected from the group consisting of a protein, a metal conjugate, a drug-metal conjugate, a DNA binding domain, and a nucleic acid insertion molecule.

[0329] In one embodiment, the conjugate can enter the cell by permeabilizing the cell membrane and translocate to the relevant genome where it can perform site-specific editing.

[0330] The present invention also discloses the process of using the conjugate of the present invention to transfer CRISPR-RNP into cells.In one embodiment, the disclosed process can further be used in gene editing technology to facilitate the non-viral approach to edit, remove and / or add new genes to existing genes.

[0331] In one embodiment of the present disclosure, a process is provided for transferring a CRISPR-RNP as described herein into a cell, wherein the cell is either a prokaryotic or eukaryotic cell.

[0332] In one embodiment of the present disclosure there is provided a conjugate as described herein, wherein the conjugate is used as a transfection agent.

[0333] In one embodiment of the present disclosure there is provided a conjugate as described herein, wherein the conjugate is for use in gene therapy. EXAMPLES

[0334] Example - Cell-permeable molecules containing functional molecules Here, the present disclosure is illustrated with actual examples, which are intended to illustrate the work of the present disclosure and are not intended to be taken as limiting to imply limitations on the scope of the present disclosure.Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present disclosure belongs.Although similar or equivalent methods and materials to those described herein can be used to carry out the disclosed processes and compositions, exemplary processes, devices and materials are described herein.It is understood that this disclosure is not limited to the specific methods and experimental conditions described, and such processes and conditions can be changed.

[0335] In the following examples, methods and protocols are provided for carrying out plasmid and protein studies. Protocols for obtaining conjugates, labeling of proteins, and methods for carrying out cell penetration studies using protein-drug conjugates and protein-labeled conjugates are also provided. The results section illustrates the proof-of-concept of the cell penetration ability of the conjugates disclosed in the present invention. In vitro labeling of different cell lines was carried out using the conjugates of the present invention according to the disclosed methods. Assays were also carried out using drug-protein conjugates to study the ability of the conjugates to enhance drug uptake by cell penetration.

[0336] material and method The dye Hoechst 33342 was sourced from Invitrogen, and NHS-coumarin, as well as ATTO520-NHS, ATTO390-NHS, and ATTO647N-NHS were sourced from Sigma. Organic solvents and reagents used for UV-visible spectrophotometry and CD spectroscopy were sourced from Sigma and Merck. Reagents for studying plasmid expression and protein purification were sourced from Sigma Aldrich and Merck. Reagents required for MTT assay were sourced from MP Biomedicals. Ruthenium metal complexes were sourced from Sigma.

[0337] Example 1 Plasmid / Protein Studies - A plasmid containing the AlbG gene as shown in SEQ ID NO:19 was obtained by previously published methods (Vetting et al. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2011:67(3):296-302, the contents of which are incorporated herein by reference and specific details are provided below).

[0338] The open reading frame of AlbG was amplified by standard PCR techniques using X. albilineans (ATCC29184; Pieretti et al., BMC Genomics, 2009, 10:616, 1-15) chromosomal DNA as template. Oligonucleotides AlbGF (5'-ATCCCGCTCATATGCCGGCCAAGACCCTTG-3') and AlbGR (5'-ATCCCGCTCTCGAGTCAATCGGACAGCTCGATATC-3'), containing NdeI and XhoI restriction sites, respectively, were used. The PCR fragment was cloned into pET-28a(+) and recombinant AlbG carrying a thrombin-cleavable N-terminal His6 tag was expressed in E. coli strain BL21(DE3). For shake flask growth, 1 liter of Luria broth medium supplemented with kanamycin (35 μg / ml) was inoculated with 10 ml of overnight culture and incubated at 37 °C. Cultures were grown in mid-logarithmic phase (A of approximately 0.8). 600), cooled to 20 °C, induced with 0.5 mM IPTG, and further incubated overnight at 20 °C. All purification procedures were performed at 4 °C. Cells were harvested by centrifugation at 3000 g, resuspended in buffer A [50 mM Tris-HCl, pH 7.8 containing 300 mM NaCl, protease inhibitors, lysozyme (5 μg / ml) and DNase I (0.1 μg / ml)] and stirred for 20 min. Cells were then lysed by sonication and cell debris was removed by centrifugation at 10000 g for 30 min. The supernatant was loaded onto a nickel-nitrilotriacetic acid (Ni-NTA) column pre-equilibrated with buffer A and washed with 10 column volumes of the same buffer. Bound proteins were eluted with a linear imidazole gradient from 0 to 0.3 M, and peak fractions were pooled and concentrated.

[0339] A plasmid containing the EfsQNR gene as shown in SEQ ID NO:2 was obtained by a previously published method (Hegde et al., Antimicrob. Agents Chemother. 2011 Jan;55(1):110-117, the contents of which are incorporated herein by reference and details are provided below).

[0340] The open reading frame of EfsQNR was amplified by standard PCR techniques using E.faecalis V583 (ATCC700802; ENTFA226185) chromosomal DNA as a template. Oligonucleotides (5'-ATCCCGCTCATATGAAAATAACTTATCCCTTGCCA-3') and (5'-ATCCCGCTCTCGAGTTAGGTAATCACCAAACCAAGT-3'), containing NdeI and XhoI restriction sites, respectively, were used. The PCR fragment was cloned into pET-28a(+) and recombinant EfsQNR carrying a thrombin-cleavable N-terminal His6 tag was expressed in E.coli strain BL21(DE3). For shake flask growth, 1 liter of Luria broth medium supplemented with kanamycin (35 μg / ml) was inoculated with 10 ml of overnight culture and incubated at 37 °C. Cultures were grown in mid-logarithmic phase (A of approximately 0.8).600 ), cooled to 20°C, induced with 0.5 mM isopropyl-β- d -thiogalactopyranoside (IPTG), and further incubated overnight at 20°C.

[0341] Cells were harvested by centrifugation at 1,200 g and resuspended in buffer A (50 mM Tris-HCl [pH 7.8], 300 mM NaCl) containing protease inhibitors, lysozyme (5 μg / ml), and DNase I (0.1 μg / ml), and the mixture was stirred for 20 min. Cells were then lysed by sonication, and cell debris was removed by centrifugation at 10,000 g for 30 min. The supernatant was loaded onto a Ni-NTA column pre-equilibrated with buffer A and washed with 10 column volumes of the same buffer. Bound proteins were eluted with a linear imidazole gradient from 0 to 0.3 M, and fractions were pooled and concentrated.

[0342] As a comparative example, a plasmid containing the TtCuA gene as shown in SEQ ID NO: 13 was obtained by the method of Biochemistry, 2008, 47, 1309-1318, which is incorporated herein by reference.

[0343] Example 2 Toxicity assay - An industry standard MTT assay (e.g., Sigma Aldrich) was performed to analyze the toxicity of β-helical protein-cytotoxic drug conjugates on mammalian cells, e.g., HeLa cells. Cells were cultured using standard protocols. One million cells were seeded in confocal plates (1 cm dishes) and grown for 6-8 hours. A mixture of cytotoxic drug and EfsQNR protein (mixed in a 2:1 ratio) was added to the cells and incubated at room temperature for 15 minutes to 24-72 hours. After incubation, cells were washed with PBS, treated with MTT, and incubated for another 24 hours. Cells were then washed and the absorbance values ​​at 570 nm were analyzed. Live cells with an active metabolism convert MTT to a purple formazan product with a maximum absorbance around 570 nm. Dead cells cannot convert MTT to formazan, so the percentage of live cells for a given protein or any other molecule can be calculated by analyzing the absorbance values ​​at 570 nm.

[0344] Example 3 Labeling of proteins with fluorescent dyes - Fluorescent dyes were considered as an example of functional molecules to investigate the cell membrane permeation ability of conjugates. Labeling of recombinant proteins with dyes was carried out by carrying out a series of reactions in dark conditions. The protein to be labeled was taken up in PBS buffer (1X and pH 7.3) and the dye was taken up at a concentration of 2-3 times that of the protein. The protein was added to 0.1 M sodium carbonate buffer (pH 8.5) followed by the addition of the dye. The dye was added very slowly (3 μl each time) to the buffer containing the protein kept on ice with occasional shaking. The resulting solution was wrapped in aluminum foil and avoided from light. The solution was stirred for 1 h at room temperature and then purified by gel filtration, i.e. passed through a desalting column or a PD10 column with 1XPBS buffer. The resulting labeled protein was characterized using UV-visible spectrophotometry to determine the dye:protein ratio.

[0345] Example 4 Cellular uptake of labeled proteins - The uptake of labeled proteins was checked by treating mammalian cells with different labeled proteins such as AlbG (SEQ ID NO: 1), EfsQNR (SEQ ID NO: 2) and, as a comparative example, TtCuA (SEQ ID NO: 13). TtCuA is a cytochrome oxidase c protein from the organism Thermus thermophilus. It is represented by the amino acid sequence set out in SEQ ID NO: 13. Cells were seeded in confocal plates (1 cm dishes) at a concentration of 1 million and grown for 6-8 hours. Then, labeled proteins were added to the cells at various concentrations and incubated under standard conditions of 5% CO2 and 37°C. Cells were then washed twice after 3 and 24 hours with HBSS (Hank's Blank Salt Solution) or PBS and observed under a fluorescent microscope and / or a confocal laser scanning microscope.

[0346] The uptake of the labeled proteins was checked by treating E. coli and yeast (Kluveromyces) cells with different labeled proteins such as AlbG (SEQ ID NO: 1), EfsQNR (SEQ ID NO: 2). E. coli or Kluveromyces cells were inoculated and grown overnight until the OD reached 0.6. The cells were diluted 50-fold and 3 micromolar labeled proteins (conjugates) were added. The cells were further grown under standard growth conditions (37°C shaking conditions). The treated cells were then centrifuged and washed 3-4 times with PBS. The cells were then dispersed in 100 microliters of PBS and imaged by fluorescence / confocal microscopy.

[0347] Furthermore, different proteins such as AlbG (SEQ ID NO: 1), EfsQNR (SEQ ID NO: 2) labeled with green fluorescent dye (A-520) were found to be incorporated into several drug-resistant strains of bacteria (Pseudovibrio species, Ad37 / 5 / 13 / 14 and Enterobacter, where Enterobacter strains are resistant to antibiotics such as erythromycin, chloramphenicol, tetracycline, nalidixic acid, kanamycin, and penicillin), yeast cells (Saccharomyces cerevisiae, Kluveromyces marxianus, and candida albicans), plant cells (Arabidopsis), zebrafish embryos, and Drosophila embryos, as observed by confocal laser scanning microscopy.

[0348] Protocols for uptake in bacterial and yeast cells The day before the experiment, each bacterial and yeast strain was inoculated and grown overnight. Centrifuge the cells and add 2 ml of fresh medium. Add 100-200 μL of cells to the mixture. Add 10 μM green-labeled CPP. Add fresh medium to bring the volume to 1 mL. After 24 hours, the treated cells were centrifuged and washed 3-4 times with PBS. · Cells were dispersed in 100 microliters of PBS and imaged by fluorescence / confocal microscopy (Figures 25 and 26).

[0349] Protocol for uptake into plant cells (Arabidopsis) Plants were allowed to grow for 7 days before the experiment. · 20 μM of different cell-permeable proteins such as AlbG (SEQ ID NO: 1), EfsQNR (SEQ ID NO: 2) labeled with green fluorescent dye (A-520) were added to the plants in buffer [three plants grown for 7 days] in 500 μL of PBS, The mixture was placed in a growth chamber for 24 hours under standard growth conditions (continuous light supply and growth chamber kept static at 23°C). After washing the plants three times with PBS, fresh PBS was added and the cells were visualized under a microscope. To avoid interference, unstained cells such as root and stem cells were selected for visualization (Figures 23 and 24).

[0350] Protocols for incorporation into zebrafish and Drosophila embryos Zebrafish and Drosophila embryos were harvested and washed with PBS. · 10 μM of different cell-permeable proteins such as AlbG (SEQ ID NO: 1), EfsQNR (SEQ ID NO: 2) labeled with green fluorescent dye (A-520) were added to the vials containing the embryos and incubated for 2 hours; Embryos are collected, washed 3 times with PBS, dispersed in PBS, placed on glass coverslips and visualized under a microscope (Figures 27, 28).

[0351] These results show that the CPPs of the present invention can import cargo into the cytoplasm of a wide variety of cell types by crossing the cell membrane and / or cell wall. This opens the possibility of conjugating the CPPs with antibiotics such as ciprofloxacin and penicillin or any other antibiotics by conjugating the carboxylic acid (-COOH) group of the drug with the amine group (from the lysine residue) of the CPP using activated acid coupling chemistry (EDC / NHS). These reactions are well known in the literature and textbooks (Reference: Bioconjugate Techniques by Greg T Hermansen, pages 264-265). The use of linkers such as adipic acid dihydrazide, succinimidyl 6-hydrazinonicotinate acetone hydrazine, C6-succinimidyl 6-hydrazinonicotinate acetone hydrazine, succinimidyl hydrazinium nicotinate hydrochloride to conjugate the CPPs with antibiotics. These linkers are known to be hydrolyzed under intracellular conditions, releasing the antibiotic intracellularly.

[0352] Antibiotic-CPP conjugates improve the efficiency of cellular uptake when compared to unconjugated antibiotics and reduce or eliminate drug efflux by cellular mechanisms such as glycoproteins. While the binding site for glycoproteins is in the region of <1 kDa, CPP-drug conjugates are of 48 KDa size. This can help improve older antibiotics and contribute to addressing the problem of antimicrobial resistance. Similarly, this technology can be used to improve the efficiency of antibiotic / repellent / nutrient delivery to fish and plants.

[0353] Example 5 Cellular uptake of drugs - HeLa cells were used to determine the enhanced uptake of drugs using the cell-permeable conjugates of the present invention. HeLa cells were seeded in 96-well plates at a concentration of 10,000 and grown for 6-8 hours. Ruthenium metal complexes were mixed with EfsQNR in different ratios of 1:1, 1:2, and 1:3 to form conjugates, which were then added to the cells. The conjugate formed with ruthenium and EfsQNR in a ratio of 1:2 gave improved results. Cell death after 24 hours was monitored by MTT assay as described above and correlated with the uptake rate of ruthenium-EfsQNR conjugates by HeLa cells.

[0354] Results of Examples 1 to 5 Protein and conjugate characterization Structural specificity - The size of the AlbG protein was determined from the published crystal structure pdb id:2xt2.pdb. The length was determined to be 10.7 nm and the width (diameter) to be 2.6 nm by measuring the atomic distances from end to end of the dimeric structure in Pymol®. The total formal charge was -27. Positively and negatively charged residues are arranged alternately: an arginine ladder (total of 20 Arg residues), lysine (14 residues) and the presence of aspartic acid (30 Asp residues) and glutamic acid (31 Glu residues). An asparagine (20 Asn residues) ladder along the surface of the protein.

[0355] The size of the EfsQNR protein was determined from the published crystal structure pdb id:2w7z.pdb. The length of the protein was determined to be 10.9 nm and the width (diameter) to be 2.8 nm by measuring the atomic distances from end to end of the dimeric structure in Pymol®. Total formal charge -41. Presence of alternating positively and negatively charged residues: arginine ladder (total of 16 Arg residues), lysine (12 residues) and aspartic acid (25 Asp residues) and glutamic acid (33 Glu residues). Asparagine (33 Asn residues) ladder along the surface of the protein.

[0356] For comparison, the size of the TtCuA protein was determined from the published crystal structure pdb id:2CuA.pdb. The length was determined to be 3.3 nm and the width (diameter) to be 1.9 nm by measuring the atomic distances from end to end of the structure in Pymol®. The structure contains 5 arginine residues, 4 lysine residues, 9 glutamic acid residues, and 6 asparagine residues with a total charge of -3.

[0357] Figure 1 shows the CD spectrum of the purified AlbG protein (SEQ ID NO: 1) used in the study. The protein was dialyzed in PBS and CD spectroscopy was performed in the 200-300 nm region using 1-5 micromolar concentrations. If necessary, it was further diluted in PBS. The negative value of the CD at 220 nm for this protein indicates a β-sheet (β-barrel or β-helical structure) arrangement.

[0358] Figure 2 shows the purified plasmids used for the expression of the β-helical proteins AlbG and EfsQNR, each showing the same results in triplicates (AlbG-1 to AlbG-3 and EfsQNR-1 to EfsQNR-3).

[0359] FIG. 3 shows the purified protein bands of AlbG and EfsQNR proteins in polyacrylamide gel. After performing SDS-gel electrophoresis, it was noted that the molecular weight of both proteins in monomeric form is about 30 kDa. The approximate molecular weight of the dimeric form of AlbG and EfsQNR is about 48 kDa. The proteins, AlbG and EfsQNR, were used to form conjugates with functional molecules, which were then used to study the cell permeability effect. The proteins were further tested for any cytotoxicity using HeLa cells to determine the course of the study (see "Cytotoxicity Test" below).

[0360] Figure 4 shows the results of MALDI TOF mass spectrometry of EfsQNR protein and AlbG protein. In this experiment, the proteins were dialyzed in water and samples were prepared using sinapinic acid as a matrix with 0.1% TFA and acetonitrile. 1-10 micromoles of protein were used. The results show EfsQNR protein with a molecular weight of approximately 26.5 kDa, and AlbG protein with a molecular weight of approximately 23 kDa.

[0361] Cytotoxicity Testing The toxicity of AlbG and EfsQNR proteins on HeLa cells was tested using the MTT assay described above. In the toxicity assay, placebo, control, AlbG (30 μM) and EfsQNR (30 μM) samples were used in triplicate. Table 1 shows the absorbance values ​​at 570 nm for each sample after MTT treatment. Observing the values, it can be understood that cells treated with 30 μM AlbG and 30 μM EfsQNR show 95% viability compared to the control cells. This clearly suggests that the tested proteins at the tested concentrations are not toxic to HeLa cells and are therefore safe concentrations to use in further experiments.

[0362] Table 1 shown here displays the absorbance values ​​at 570 nm in the MTT assay to assess protein toxicity.

[0363] [Table 1]

[0364] The placebo in this experiment was 20 mM Tris buffer at pH 8.0, while the control examined was HeLa cells alone without the addition of any protein or other substrates.

[0365] Labeling test Figure 4 shows the UV-visible spectrophotometry of the labeled AlbG and EfsQNR conjugates according to the procedure described above (see "Labeling of proteins with fluorescent dyes" above). The UV-visible spectra were analyzed to calculate the labeling ratio of both conjugates. The labeling ratio means the number of dyes attached per protein molecule. It is calculated by measuring the ratio between the absorbance value of the dye (at a wavelength depending on the dye used for labeling) and the absorbance of the protein at 280 nm. The dye used for labeling in this experiment was NHS-coumarin. In the case of AlbG protein, the dye:protein molecular ratio is observed to be 1.95. In the case of EfsQNR, the dye:protein molecular ratio is found to be 5.5. The UV-vis spectra confirmed that both AlbG and EfsQNR proteins were labeled with NHS-coumarin dye. In this study, the labeled proteins were further used to establish cell penetration.

[0366] Cell permeability test Figure 5 shows the fluorescence microscopy images of HeLa cells treated with AlbG, EfsQNR, and TtCuA proteins (conjugates) labeled with NHS-C. The uptake of the labeled proteins (conjugates) was compared to untreated HeLa cells, which were considered as the control set for this study. Hoechst Blue is a nuclear labeling dye used along with the NHS-C dye used to label the proteins. Proteins AlbG and EfsQNR are β-helical proteins with lengths ranging from 5 nm to 25 nm, preferably 10 nm to 15 nm, and widths ranging from 1 nm to 5 nm, preferably 1 nm to 3 nm, and represent the recombinant β-helical proteins of the present invention. However, TtCuA is a protein with a length of about 4 nm and is composed of β-strands forming a β-barrel, thereby representing a comparative example of the recombinant β-helical proteins of the present invention. These two different categories of proteins were considered for this study to establish the superior cell penetration ability of the conjugates of the present invention compared to different types of β-helical proteins.

[0367] In FIG. 5, panel A represents control cells treated with only nuclear labeling dye (Hoechst Blue), which means there is no brighter dye, panel B represents cells treated with Hoechst Blue dye and TtCuA-NHSC labeled protein (conjugate), panel C represents cells treated with Hoechst Blue dye and AlbG-NHSC labeled protein (conjugate), and panel D represents cells treated with Hoechst Blue dye and EfsQNR-NHSC labeled protein (conjugate). Observing the figure, as shown in panel B, there is significantly less fluorescence seen within the cells, indicating that there is less TtCuA-NHSC conjugate present within these cells, whereas panels C and D indicate that there is more AlbG-NHSC conjugate and EfsQNR-NHSC conjugate present within the cells. Therefore, it can be seen that the TtCuA-NHSC conjugate cannot effectively penetrate the cell membrane and enter the cells, as compared with the AlbG-NHSC conjugate and the EfsQNR-NHSC conjugate.

[0368] When comparing panels C and D, it can be observed that the EfsQNR-NHSC conjugate can permeate the membrane more efficiently compared to the AlbG-NHSC conjugate. Therefore, the cellular permeation ability of the three conjugates can be summarized in the order of increasing cellular uptake as TtCuA-NHSC < AlbG-NHSC < EfsQNR-NHSC. This further demonstrates the cellular permeation ability of conjugates containing recombinant β -helical proteins with a length of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width of 1 nm to 5 nm, preferably 1 nm to 3 nm each. Conjugates containing AlbG and EfsQNR independently can show an improvement in cellular permeability compared to conjugates containing TtCuA.

[0369] Since the conjugate containing the EfsQNR protein showed the highest ability to permeate the cell membrane, the EfsQNR protein was further tested with various dyes to enhance the labeling of mammalian cells.

[0370] Figure 22 shows real-time cell invasion proceeding through the direct interaction between the conjugate and the cell membrane. To visualize the cells under a fluorescence microscope, the cells were treated with the dye Hoechst 33342 (blue, shown dark in Figure 22) that binds to the nucleus and the dye Alexa 594-WGA (red, shown bright in Figure 22) that binds to the plasma membrane, which indicates that EfsQNR-ATTO-520NHS (green, shown as bright circles in Figure 22) efficiently permeates into the cells by a direct mechanism that bypasses the endocytosis mechanism.

[0371] Labeling of mammalian cells Figure 7 shows the ability of a conjugate containing EfsQNR conjugated with a dye in labeling HeLa cells. Figure 6 shows cells labeled with EfsQNR-ATTO-520NHS prepared according to the labeling method described above. The dye Hoechst 33342 (blue, shown dark in Figure 7) binds to the nucleus, and the dye Alexa 594-WGA (red, shown bright in Figure 7) binds to the plasma membrane. The conjugate is formed by linking the EfsQNR protein with the green fluorescent dye ATTO-520NHS (shown as the brightest dye in Figure 7). It can be clearly observed that the EfsQNR-ATTO-520NHS conjugate penetrates HeLa cells, leading to efficient labeling of the cells (panel B) when compared to the control panel A showing HeLa cells not treated with the conjugate.

[0372] FIG. 8 shows similar results in HeLa cells treated with a conjugate formed by linking the EfsQNR protein with the blue fluorescent dye ATTO-390NHS (shown brightly in FIG. 8).

[0373] Figure 9 shows similar results for microglial cells labeled with EfsQNR-ATTO-520NHS prepared according to the labeling method described above. Panel A shows significant fluorescence of the dye from inside the cells. Panel B shows microglial cells further treated with the dye Hoechst 33342 (blue, shown dark in Figure 9), which binds to the nucleus, and the dye Alexa 594-WGA (red, shown bright in Figure 9), which binds to the plasma membrane, indicating that EfsQNR-ATTO-520NHS efficiently penetrated into the cells.

[0374] Figure 10 shows similar results for keratinocyte cells labeled with the conjugate EfsQNR-ATTO-520NHS prepared according to the labeling method described above. Panel A shows significant fluorescence of the dye from inside the cells. Panel B shows keratinocyte cells further treated with the dye Hoechst 33342 (blue, shown dark in Figure 10), which binds to the nucleus, indicating that EfsQNR-ATTO-520NHS efficiently penetrates into the cells and is present near the nucleus.

[0375] FIG. 11 shows similar results for SH-SY5Y cells labeled with the conjugate EfsQNR-ATTO-520NHS prepared according to the labeling method described above.

[0376] Figure 12 shows similar results for mouse ES cells labeled with EfsQNR-ATTO-520NHS prepared according to the labeling method described above. Figure 12 shows mouse ES cells treated with the nuclear-binding dye Hoechst 33342 (blue, shown dark in Figure 12) and the plasma membrane-binding dye Alexa 594-WGA (red, shown bright in Figure 12), indicating that EfsQNR-ATTO-520NHS efficiently penetrated into the cells.

[0377] Labeling of non-mammalian cells Figures 13-14 and 21-28 show the ability of conjugates containing EfsQNR conjugated with dyes in labeling bacterial cells (E coli and Pseudovibrio AD37), yeast cells (kluveromyces and Sachromyces species), plant cells (Arabidopsis species), insect cells (Drosophila embryos) and fish cells (zebrafish embryos). Figures 13-14 and 21-28 show E coli, Pseudovibrio AD37, kluveromyces, Sachromyces species, Arabidopsis species, Drosophila embryos and zebrafish embryos, respectively, labeled with EfsQNR-ATTO-520NHS prepared according to the labeling method described above.

[0378] FACS sorting of conjugate-treated HeLa cells Figure 15 shows the results of standard FACS sorting of HeLa cells treated with the conjugate EfsQNR-ATTO-647N labeled conjugate. Treatment of cells for only 10 minutes (panel B) resulted in significant uptake of dye compared to the control (panel A), which continues to increase from 1 hour (panel C) to a maximum measured at 3 hours (panel D).

[0379] Drug uptake studies Figure 16 shows the cellular uptake of the ruthenium metal complex Ru(CO)3Cl glycinate in HeLa cells. The ruthenium metal complex was conjugated with EfsQNR protein to form a conjugate consisting of ruthenium metal complex-EfsQNR. HeLa cells were treated with the ruthenium metal complex-EfsQNR conjugate as described above (see "Cell Penetration Test" above) and the uptake of the complex was detected by performing an MTT assay to check the cell viability as described above. Observing the graph (Figure 14), it was found that when treated with the ruthenium metal complex alone, the cellular uptake was only 0.5%, whereas when treated with the ruthenium metal complex-EfsQNR protein conjugate, the cellular uptake of the complex increased to 24.4%. It can therefore be confirmed that the conjugate containing EfsQNR protein promoted a 50-fold higher cellular uptake compared to the ruthenium metal complex alone. This enhanced uptake can be further exploited by using the conjugates of the present invention to deliver many life-saving drugs to the target, thereby reducing the drug dose and subsequently reducing side effects.

[0380] FIG. 17 shows the results of a viability test of mammalian cells (HeLa and HepG2) cultured with a conjugate containing EfsQNR protein linked to the chemotherapy drug Cisplatin® (cisplatin or cis-diamminedichloroplatinum(II) (CDDP)), labeled as "CYDD" in FIG. 17. Mammalian cells (HeLa: panel A, or HepG2: panel B) were cultured using a standard protocol. One million cells were seeded in a confocal plate (1 cm dish) and grown for 8 hours. A conjugate containing Cisplatin® and EfsQNR (prepared according to the method described above in a molar ratio of 2:1) was then added, and the culture was maintained at room temperature for 15 minutes. The cells were maintained under standard growth conditions for 24 and 72 hours. The cells were then washed with PBS and MTT solution was added. After the formazan dye was formed, it was dissolved in DMSO and the absorbance at 550 nm was measured. The results show that in both cell types tested, the same cytotoxic effects of Cisplatin® are exhibited at lower doses when the drug is delivered as a conjugate according to the present invention.

[0381] It is noted that in all experiments tested, similar results were obtained when the EfsQNR protein was replaced by the AlbG protein.

[0382] advantage Overall, it can be concluded that conjugates containing recombinant β-helical proteins of specific length and width and functional molecules can act as highly efficient cell membrane permeable conjugates. The ability of the conjugates to directly permeate the cell membrane provides an advantage compared to the endocytic entry mechanism. Practical examples of AlbG-NHSC and EfsQNR-NHSC conjugates are provided in this disclosure to demonstrate their ability to permeate the cell membrane. EfsQNR-dye conjugates have been shown to improve the labeling ability of various mammalian and non-mammalian cells due to their ability to effectively permeate the cell membrane. Conjugates containing EfsQNR and / or AlbG have been shown to increase the cellular uptake of drugs including ruthenium metal complexes and Cisplatin® in HeLa and HepG2 cells. This ability can be further exploited to enhance the uptake of various anticancer drugs by cancer cells, which can facilitate treatment by selectively targeting cancer cells in an efficient manner and at the same time reducing the required amount of drugs. Reducing the dose of anticancer drugs can also avoid side effects associated with the administration of such drugs.

[0383] Example - Cell-penetrating molecules containing nucleic acids In the following paragraphs, practical examples are provided for delivering nucleic acid such as plasmids carrying genes of interest into cells by penetrating cell membrane.The delivery is made possible by using conjugates (cell penetrating peptides as described herein) that further comprise nucleic acid molecules or plasmids.The examples also depict the expression of genes of interest after penetrating cell membrane and entering cells.

[0384] The first example describes the transfection of a gene of interest into cells using an embodiment of the conjugate of the present invention, where the gene of interest is mcherry, which encodes RFP (red fluorescent protein). A plasmid containing the mcherry gene is linked to a protein to form a conjugate, which includes EfsQNR protein and copper [II] phenanthroline. The conjugate is used to transfect HeLa cells. The successful expression of the mcherry gene in HeLa cells is shown as a proof of concept to establish the ability of the conjugate to penetrate cell membranes and transfect cells.

[0385] material and method Copper phenanthroline complex was obtained commercially.

[0386] Example 6 Protein studies - Studies governing expression, incubation conditions, and purification of EfsQNR plasmid were performed according to those previously published (Hegde et al. Antimicrob. Agents and Chemother. 2011:55(1):110-7, which is incorporated herein by reference) to obtain EfsQNR protein. SDS-PAGE (polyacrylamide gel electrophoresis) was performed using a Bio-Rad kit, and protein bands were visualized using a 12% polyacrylamide gel.

[0387] Example 7 Preparation of plasmid conjugates - copper[II]phenanthroline conjugates As disclosed in the present invention, a conjugate is prepared for transfecting cells, the conjugate comprising EfsQNR (SEQ ID NO: 2), copper[II]phenanthroline, and a plasmid carrying a gene of interest.

[0388] Figure 18 shows the vector map of the plasmid carrying the mcherry gene (SEQ ID NO: 25) used in the preparation of the conjugate in this example. The EfsQNR protein (SEQ ID NO: 2) is a β-helical protein with pentapeptide repeats (as represented in SEQ ID NO: 18) having a length in the range of 5 nm to 25 nm, preferably 10 nm to 15 nm, and a width of 1 nm to 5 nm, preferably 1 nm to 3 nm. Copper[II]phenanthroline is the nucleic acid intercalating agent used as a linker in this example.

[0389] The EfsQNR protein obtained by controlling the expression of EfsQNR plasmid is complexed with copper [II] phenanthroline complex to obtain a complex containing EfsQNR and copper [II] phenanthroline. The obtained complex is further reacted with a plasmid carrying mcherry gene to obtain a conjugate according to an embodiment of the present invention. The obtained conjugate is used to transfect HeLa cells.

[0390] Figure 19 shows two schemes for preparing conjugates that can be used for transfection. Scheme 1 suggests using copper [II] phenanthroline as a linker to form a complex with a protein. The resulting complex is further reacted with a plasmid carrying the gene of interest to obtain the conjugate used for transfection.

[0391] Scheme 2 suggests the use of a DNA-binding protein as a linker to form a complex with a protein. The resulting complex is further reacted with a plasmid carrying the gene of interest to obtain the conjugate used for transfection.

[0392] In this example, copper [II] phenanthroline is used as a linker to form the complex, and recombinant β-helical protein-EfsQNR (SEQ ID NO: 2) is used together with a plasmid containing the mcherry gene. The following protocol was used to prepare the complex and conjugate.

[0393] Protein EfsQNR was mixed with copper[II]phenanthroline in a 1:2 molar ratio and incubated at room temperature for 30 minutes to obtain a complex. A plasmid containing mcherry gene was mixed with the complex obtained in the previous step and incubated at 4°C for 30 minutes to obtain a conjugate. The conjugate thus obtained was used to transfect HeLa cells.

[0394] Example 8 Transfection of HeLa cells using the conjugate of Example 7 Figure 20 shows a scheme of the transfection experiment using the conjugate obtained in Example 7. In this example, the following conditions were used to carry out the transfection experiment:

[0395] The conjugate containing the mcherry plasmid obtained in Example 7(A) was added to HeLa cells (8 hours after seeding). The cells were allowed to grow by incubating at 37°C and 5% CO2 for 48 hours. After incubation, the cells were observed under a confocal microscope.

[0396] Figure 21 shows confocal microscopy images of HeLa cells after transfection experiments. RFP expression can be observed as bright (red) dots in HeLa cells, demonstrating the cell permeability and transfection ability of the conjugates disclosed herein.

[0397] Example 9 Preparation of plasmid conjugates - ethylenediamine conjugation As further disclosed in the present invention, a conjugate was prepared for transfecting cells with a plasmid typical for encoding one or more gene editing molecules. The conjugate included EfsQNR (SEQ ID NO: 2), an ethylenediamine linker, and a plasmid. The conjugate was prepared according to a known protocol (see Bioconjugate Techniques; Greg T. Hermansen; Academic Press; 3 rd edition; 2013; pp264-265, which is incorporated herein by reference). The plasmid used was a 2.7 kb red-labeled circular plasmid DNA (Label IT® Plasmid Delivery Control Cy®3 (product code MIR 7904) obtained from Mirus Bio).

[0398] Example 10 Transfection of MCF7 cells using the conjugate of Example 9 The conjugate containing the plasmid obtained in Example 9 [Label IT® Plasmid Delivery Control Cy® 3 (product code MIR 7904)] was added to MCF-7 cells (8 hours after seeding). The cells were allowed to grow by incubating at 37°C and 5% CO2 for 12 to 16 hours. After incubation, the cells were observed under a confocal microscope.

[0399] Figure 30 shows (A) the results of a transfection experiment in MCF7 cells using the conjugate (EfsQNR) (SEQ ID NO: 2) obtained in Example 1 and a 2.7 kb red-labeled circular plasmid DNA (product code MIR 7904) commercially available from Mirus Bio, and (B) the results of a transfection experiment in MCF7 cells using a control of the red-labeled plasmid used above in the absence of the conjugate. (i) shows the maximum projection of the cells after incubation, (ii) is the image corresponding to the intensity plot of the cells after incubation, and (iii) shows the intensity plot of the cells after incubation.

[0400] In the maximum projection image (i), it can be clearly seen that the plasmid spreads much better throughout the cell when conjugated to the EfsQNR protein, indicating the efficiency of the conjugate to carry and localize target nucleic acids such as plasmids inside the cell.

[0401] From the intensity plot (iii) it is evident that the plasmid is able to enter the cells with the help of proteins and the spreading is uniform and widespread.

[0402] The examples presented herein show the use of protein EfsQNR (SEQ ID NO:2) in the preparation of conjugates for transfection, however, proteins having amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:3 through SEQ ID NO:12 can also be effectively used to form conjugates. Also, recombinant beta helix proteins having pentapeptide repeat sequences as shown in SEQ ID NO:18, with lengths in the range of 5 nm to 25 nm, preferably in the range of 10 nm to 15 nm, and widths in the range of 1 nm to 5 nm, preferably in the range of 1 nm to 3 nm, can be used to prepare the conjugates described in this disclosure. Similarly, the examples show the use of copper[II]phenanthroline or ethylenediamine as linkers, however, other molecules such as DNA binding proteins, metal conjugates, drug metal conjugates, and other nucleic acid intercalating molecules can also be used in the formation of conjugates that are effectively used as transfection agents. One class of DNA binding proteins, i.e., zinc finger proteins, having molecular weights less than 12 kDa, can also be used to form conjugates. One such zinc finger protein that can be used as a linker is shown in SEQ ID NO: 24. In the present disclosure, a plasmid carrying the mcherry gene ( FIG. 18 ) and a 2.7 kb red-labeled circular plasmid DNA were used to prepare a conjugate for transfection, and the expression of the mcherry gene was shown as a proof of concept. For transfection purposes, it is contemplated that essentially any nucleic acid or plasmid containing a gene of interest can be complexed with the complexes disclosed herein to form a conjugate for use in gene therapy or gene editing.

[0403] advantage The present disclosure provides a conjugate that comprises a nucleic acid or plasmid that comprises a gene of interest, and has the ability to permeate cell membrane and express the gene of interest.Therefore, the conjugate can be used for transfection, and has a very large potential for use in gene therapy and gene editing.It is known that the delivery of the nucleic acid and plasmid that constitutes a gene into cells is a major challenge in the field of gene therapy and gene editing, so the disclosed conjugate opens a new avenue in this field.The disclosed conjugate is easy to prepare and can be complexed with a wide variety of nucleic acids and plasmids that constitute genes used in gene therapy and gene editing.

[0404] Example 11 Transfection of gene editing molecular machinery with the CPPs of the present invention Transfection experiments were carried out in mammalian cells using the conjugate (EfsQNR: SEQ ID NO: 2) obtained in Example 1 and gene editing complex based on endonuclease Cas9, CRISPR-RNP. The results shown in Table 2 are shown in Figure 29. Based on the results of Example 4 above, it is contemplated that the application of this technology can be applied to a wide variety of cells, including bacterial cells, yeast cells, plant cells, insect cells and fish cells.

[0405] [Table 2]

[0406] In one embodiment of the present invention, the following conditions were used to perform the transfection experiments.

[0407] strategy: Gene editing in cells has been reported in a variety of ways. One particularly relevant example delivers a ribonucleoprotein (RNP) complex of an endonuclease such as Cas9 and a gRNA into cells. This methodology is particularly attractive because it does not require intermediate intracellular synthesis of the gene editing machinery.

[0408] Currently, several methods, including electroporation, microinjection, nanoparticle- and cationic lipid-mediated delivery, are used to introduce the gene editing machinery into the cell's cytoplasm from where it can migrate into the genome.

[0409] In one embodiment, the present invention uses electrostatic interactions between Cas9, gRNA, and CPP to deliver Cas9-gRNA RNP (CRISPR-RNP) to cells. The use of conjugates in which the various components are linked by covalent and / or non-covalent interactions is also contemplated.

[0410] Cells expressing eGFP (HEK293) are transfected with CRISPR-RNP with gRNA specific for eGFP. The uptake of CRISPR-RNP is mediated by the CPP of the present invention, which can efficiently transport cargo into cells (Example 4). Following uptake into cells that is dissociated from the CPP or not inhibited by the CPP, Cas9 is directed by the gRNA to its target DNA sequence eGFP. The knockout of this gene, and thus the loss of fluorescence in cells, is evidence of an efficient and effective delivery method of gene editing complexes.

[0411] To obtain a stable eGFP-expressing cell line, a selection process using G418 antibiotic is used. Cells that express eGFP and therefore incorporate the eGFP plasmid will also be resistant to the G418 antibiotic. Cells that do not incorporate the eGFP plasmid will die after a certain period of time if kept in the selection medium because they are not resistant to G418.

[0412] Experiment: Cells (HEK293) expressing eGFP (enhanced green fluorescent protein) are obtained by transfecting HEK293 cells with eGFP using a lipofectamine-based commercial reagent. Grow the cells for 48 h to obtain 70-80% cells transfected with eGFP. Subculture the cells and grow them in selective medium containing G418 antibiotic to ensure that HEK293 cells stably express eGFP before using them for gene editing experiments.

[0413] Approximately 5000 cells are seeded into 96-well plates and grown overnight on day 1.

[0414] On day 2, the Cas9-gRNA-CPP (CRISPR-RNP-CPP) complex was formed in two steps.

[0415] Step 1: Cas9 was mixed with gRNA i) in phosphate buffered saline (PBS) or ii) in commercially available Cas9-supplied reaction buffer (Genaxxon Biosciences: Cas9-NLS-tagRFP Streptococcus (S.) pyogenes Cas9 protein NLS followed by a C-terminal red fluorescent protein (tagRFP) tag sequence; Product No.: S5306.0010, HS-No.: 35040090). The reaction buffer acts to stabilize the complex between Cas9 and RNP. The mixture was then incubated at room temperature for 25 min to form the CRISPR-RNP complex.

[0416] Step 2: 1 microM of CPP in PBS was added to the Cas9-gRNA mixture obtained in step 1 and incubated for another 30 min at room temperature to form the CRISPR-RNP-CPP complex.

[0417] Step 3: The CRISPR-RNP-CPP complex obtained in step 2 is added to the cells in culture medium (Dulbecco's Modified Eagle Medium (DMEM) with or without serum, e.g., Sigma) and the cells are cultured for 4 hours. After 4 hours, culture medium (DMEM with serum) is added to the cells and they are left to grow under standard cell growth conditions (temperature 37 °C and 5% CO2) for 48 hours. After 48 hours, the cells are washed with PBS, fresh medium (DMEM with serum) is added, and the fluorescence intensity due to eGFP is measured with a fluorescent plate reader.

[0418] Results in mammalian kidney HEK293 cells The CPP of the present invention supports the efficient delivery of CRISPR-RNP into cells. Following uptake into cells, Cas9 is directed to its target DNA sequence of eGFP by gRNA. The knockout of this gene by Cas9 leads to the loss of fluorescence in cells.

[0419] Using serum-free medium in step 3 and reaction buffer (provided by a commercial source for dissolving Genaxxon Cas9 and gRNA, product number S5306.0010) in step 1 reduced the fluorescence by 30%, indicating efficient transfer of CRISPR-RNP inside the cells.

[0420] When PBS (phosphate buffered saline) was used to dissolve the CRISPR-RNP complexes, no significant change in fluorescence intensity was observed.

[0421] Without wishing to be bound by theory, it is hypothesized that PBS is unable to stabilize the complex formation between CRISPR-RNP and CPP.

[0422] Example 12 Transfection of fluorescently labeled endonuclease Cas9 with recombinant β-helical protein of the present invention FIG. 31 shows the results of transfection experiments in MCF-7 cells using the conjugate obtained in Example 1 (EfsQNR: SEQ ID NO: 2) and the endonuclease cas9 tagged with either (i) a red fluorescent protein or (ii) the green fluorescent dye Atto520.

[0423] The conjugate obtained in Example 1 (EfsQNR: sequence number 2) was mixed in a 1:1 ratio with cas9 (e.g., Eupheria Biotech) conjugated with either red fluorescent protein or green fluorescent dye ATTO520 (Sigma product 77810) and incubated at room temperature for 30 minutes.

[0424] The resulting solution was added to the cells and incubated with the cells for 12 to 16 hours.

[0425] FIG. 31 shows (A) a maximum projection of the cells after incubation, (B) an intensity plot of the cells after incubation, and (C) a 3D depth image of the cells after incubation.

[0426] In both maximum projection images (A), it can be clearly seen that cas9 can be successfully transfected and spread throughout the cells regardless of the labeling dye, demonstrating the efficiency of the conjugate of the present invention to deliver and localize target proteins within the cells.

[0427] From the intensity plot (B), it is clear that cas9 was able to enter cells using the conjugate, regardless of the companion dye: spreading is throughout the cell and uniform.

[0428] The 3D depth image (C) shows that the Cas9 cargo is spread throughout the cell, and the depth analysis and 3D representation show that it is present in all planes.

[0429] Example 13 Transfection of fluorescently labeled gRNA with recombinant β-helical protein of the present invention As further disclosed in the present invention, a conjugate was prepared for transfecting cells with a gRNA typical for use in gene editing using the CRISPR-cas9 gene editing system. The conjugate was composed of EfsQNR (SEQ ID NO: 2), an ethylenediamine linker, and a gRNA tagged with green fluorescent dye MFP488 (e.g., Eupheria Biotech: esiCRISPR Kit-wt). The conjugate was prepared according to a known protocol (see Bioconjugate Techniques; Greg T. Hermansen; Academic Press; 3 rd edition; 2013; pp 264-265, which is incorporated herein by reference).

[0430] 32 shows the results of a transfection experiment in MCF-7 cells using (A) the conjugate (EfsQNR) obtained in Example 1 and gRNA tagged with the green fluorescent dye MFP488, and (B) a control gRNA tagged with the green fluorescent dye MFP488 in the absence of the conjugate. (i) shows the maximum projection of the cells after incubation, (ii) shows a 3D depth image of the cells, (iii) is an image corresponding to the intensity plot of the cells after incubation, and (iv) shows the intensity plot of the cells after incubation.

[0431] The images clearly show that the intensity and uniformity of gRNA in cells is significantly lower in the control compared to cells incubated with gRNA and conjugate, suggesting that the conjugate can deliver gRNA into cells. Maximum projection images, intensity plots, and 3D depth images for the control show that most of the gRNA is localized to the cell membrane, whereas for the conjugate, the distribution is clearly observed mainly in the cytoplasm.

[0432] CRISPR components were obtained from two different commercial sources: Eupheria Biotech and Genaxxon.

[0433] Genaxxon Biosciences: GFP-targeting guide RNA for CRISPR; product number: P2008.0010, purified gRNA targets a sequence encoding a highly sensitive GFP, HS-No.: 29349990).

[0434] Genaxxon Biosciences: Cas9-NLS-tagRFP Streptococcus (S.) pyogenes Cas9 protein NLS followed by a C-terminal red fluorescent protein (tagRFP) tag sequence; Product No.: S5306.0010, HS-No.: 35040090).

[0435] Eupheria Biotech: esiCRISPR Kit-wt, a kit that includes: ·20μg Streptococcus pyogenes Cas9-NLS (650ng / μl) 15μg of custom guide(g)RNA (400ng / μl) 35μl of CRISPRfection™ Transfection Reagent (a proprietary lipid-based transfection reagent suitable for delivering Cas9 protein loaded with single-stranded guide (g)RNA into most adherent cells) 1ml of CRISPRfection buffer (diluent for CRISPRfection) 5 μg of NoTarget gRNA (human, mouse, rat) as a negative control Reaction buffer for performing indel analysis of PCR products derived from DNA isolated from transfected cells Positive control reagents to confirm the performance of Cas9-NLS protein and gRNA: control target DNA, control gRNA, reaction buffer Application manual with protocols for transfection, indel analysis, and Cas9 activity assays [https: / / www.eupheria.com / products / crisprcas9 / esicrispr-kits / ; accessed February 25, 2019]

[0436] Strategies to ensure cells still retain the plasmid but use the edited non-fluorescent eGFP eGFP and RFP - the "m-cherry" construct expressing both green and red fluorescence. Transfection of mammalian cells with this plasmid allows one to determine whether the cells express eGFP and have been delivered successfully. Cells that fluoresce red rather than green indicate the loss of eGFP conferred by gene editing following CRISPR-RNP-CPP delivery.

[0437] Strategies to improve cellular uptake and gene editing (deletion, substitution, or mutagenesis) Optimization of conditions for successful delivery of the CPP-Cas9-gRNA complex can be achieved by several strategies.

[0438] Strategy 1: It is hypothesized that certain tailored buffers may enhance the interaction between CPPs and CRISPR-RNPs. The following variations are contemplated to increase the efficiency of intracellular delivery: i) addition of crowding agents (PEG 4000, cholesterol) to promote CRISPR-RNP-CPP complex formation; ii) the addition of specific small lipids (1,2-dioleoyl-3-trimethylammonium-propane, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) to promote CRISPR-RNP-CPP complex formation by promoting hydrophobic interactions; iii) small molecules such as phorbol 12-myristate 13-acetate (to enhance the micropinocytosis process within cells) iv) Changes in pH and ionic strength (to promote electrostatic interactions between CPP-Cas9-gRNA)

[0439] Strategy 2: The CPP can be functionalized with 3-(N-succinimidyloxyglutaryl)aminopropyl, polyethylene glycol-carbamyl distearoyl phosphatidyl-ethanolamine and / or N-(aminopropyl polyethylene glycol)carbamyl distearoyl phosphatidyl-ethanolamine. This functionalization can enhance the interaction of the CPP with lipid molecules of the cell membrane and facilitate cell entry of the CRISPR-RNP-CPP complex of the present embodiment.

[0440] Strategy 3: It is hypothesized that the same approach used with CRISPR endonucleases can also be used with other gene editing endonuclease systems such as ZFNs and TALENs.

[0441] It will be understood that different embodiments of the invention described herein can be combined where appropriate and features of embodiments of the invention can be used interchangeably with other embodiments where appropriate.

[0442] Although specific embodiments of the present invention have been disclosed in detail herein, this has been done by way of example and for illustrative purposes only. The above-described embodiments are not intended to limit the scope of the appended claims. The inventor contemplates that various substitutions, changes, and modifications may be made to the present invention without departing from the spirit and scope of the present invention as defined by the claims.

[0443] [Table 3] TIFF0007582956000004.tif248168TIFF0007582956000005.tif248168TIFF0007582956000006.tif12168Alternative expressions of the inventive concepts are described in the following items: 1. A cell-permeable conjugate comprising a recombinant β-helical protein linked to a functional molecule, wherein the length of the β-helical protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm. 2. The conjugate according to claim 1, wherein the length of the β-helical protein is in the range of 10 nm to 15 nm and the width is in the range of 1 nm to 3 nm. 3. The conjugate of paragraph 1 or 2, wherein the beta helix protein comprises one or more amino acid ladder structures selected from the group consisting of an arginine ladder, a lysine ladder, an asparagine ladder, an aspartic acid ladder, and a glutamic acid ladder. 4. The conjugate of paragraph 3, wherein, if present, the arginine ladder contains 10-20 arginine residues, the lysine ladder contains 10-30 lysine residues, the asparagine ladder contains 10-40 asparagine residues, the aspartic acid ladder contains 10-40 aspartic acid residues, and the glutamic acid ladder contains 10-40 glutamic acid residues. 5. A conjugate according to any one of paragraphs 1-4, wherein the beta helical protein has a total charge that is less than zero. 6. The conjugate according to claim 5, wherein the β-helical protein has a total charge of -20 to -60. 7. β-helical proteins have a strength of 0.2–12 N / m as measured by atomic force microscopy. 2 7. The conjugate according to any one of items 1 to 6, having a β-helical structure (beta-helix) having a rigidity parameter K of 1: 8. The conjugate according to any one of paragraphs 1 to 7, wherein the β-helical protein is a pentapeptide repeat protein. 9. The conjugate of paragraph 8, wherein the beta helix protein comprises a tandem repeat pentapeptide having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5. 10. The conjugate described in any one of paragraphs 1 to 7, wherein the β-helical protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof. 11. The conjugate described in any one of paragraphs 1 to 10, wherein the recombinant beta helix protein is linked to the functional molecule via a linker molecule selected from the group consisting of polyethylene glycol (PEG), a peptide, a metal conjugate, a drug-metal conjugate, a DNA binding domain, a nucleic acid insert molecule, and combinations thereof. 12. The conjugate according to paragraph 11, wherein when the linker molecule is a peptide, the peptide comprises amino acids selected from the group consisting of aliphatic amino acids, aromatic amino acids, and combinations thereof. 13. The conjugate of any one of paragraphs 1 to 12, wherein the linker is linked to the recombinant beta helix protein by covalent bonds, non-covalent bonds, and combinations thereof. 14. A conjugate according to any one of claims 1 to 13, wherein the recombinant β-helical protein is linked to the functional molecule via an ester bond or an amide bond. 15. The conjugate of any one of paragraphs 1 to 14, wherein the functional molecule is selected from the group consisting of dyes, drugs, metals, drug-metal conjugates, proteins, enzymes, antibodies, nucleic acids, polysaccharides, nuclear localization signals, nanoparticles, and combinations thereof. 16. The conjugate of any one of paragraphs 1 to 15, wherein the conjugate further comprises a signal sequence, which directs the conjugate to a particular cell or portion of a cell. 17. The conjugate according to paragraph 16, wherein the signal sequence is selected from the group consisting of SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17. 18. The conjugate of any one of paragraphs 1 to 17, wherein the conjugate further comprises a phosphatidylcholine molecule. 19. The conjugate of any one of paragraphs 16 to 18, wherein the conjugate transfers a functional molecule to a location selected from the group consisting of organelles, the nucleus, the endoplasmic reticulum, mitochondria, cell membrane, and P-cadherin-overexpressing breast cancer cells. 20. The conjugate according to paragraph 19, wherein the organelle is selected from the group comprising actin filaments, Golgi apparatus, cell membrane, microtubules. 21. The conjugate according to any one of claims 1 to 20, wherein the conjugate is used as a cell labeling agent. 22. The conjugate according to any one of claims 1 to 20, wherein the conjugate is used to transfer a functional molecule into a cell. 23. A process for transferring a functional molecule into a cell, the process comprising: a) linking a functional molecule to a recombinant beta-helical protein to obtain a conjugate; b) contacting the conjugate with at least one cell; The process, wherein contacting the conjugate of step (b) transfers the functional molecule into the cell, and the length of the beta helical protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm. 24. The process comprises, after step (b), c) detecting the entry of the conjugate into the cell. 25. The process according to paragraph 23 or 24, wherein the length of the β-helical protein is in the range of 10 nm to 15 nm and the width is in the range of 1 nm to 3 nm. 26. The process according to any one of clauses 23 to 25, wherein the beta helical protein comprises one or more amino acid ladder structures selected from the group consisting of an arginine ladder, a lysine ladder, an asparagine ladder, an aspartic acid ladder, and a glutamic acid ladder. 27. The process of paragraph 26, wherein, if present, the arginine ladder contains 10-20 arginine residues, the lysine ladder contains 10-30 lysine residues, the asparagine ladder contains 10-40 asparagine residues, the aspartic acid ladder contains 10-40 aspartic acid residues, and the glutamic acid ladder contains 10-40 glutamic acid residues. 28. The process according to any one of clauses 23 to 27, wherein the beta helical protein has a total charge that is less than zero. 29. The process according to paragraph 28, wherein the beta helical protein has a total charge of -20 to -60. 30. β-helical proteins have a strength of 0.2-12 N / m as measured by atomic force microscopy. 2 30. The process according to any one of items 23 to 29, wherein the nucleic acid has a β-helical structure (beta-helix) having a stiffness parameter K of 0.1 to 0.5. 31. The process according to any one of clauses 23 to 30, wherein the beta helical protein is a pentapeptide repeat protein. 32. The process according to item 31, wherein the beta helical protein comprises a tandem repeat pentapeptide having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5. 33. The process according to any one of clauses 23 to 30, wherein the beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof. 34. The process of any one of paragraphs 23 to 33, wherein the functional molecule is selected from the group consisting of dyes, drugs, metals, drug-metals, proteins, enzymes, antibodies, nucleic acids, polysaccharides, nuclear localization signals, nanoparticles, and combinations thereof. 35. The process according to any one of clauses 23 to 34, wherein the functional molecule is linked to the recombinant beta helix protein by covalent bonds, non-covalent bonds, and combinations thereof. 36. The process according to any one of paragraphs 23 to 35, wherein the cell is selected from the group consisting of a eukaryotic cell, a prokaryotic cell, and a combination thereof. 37. The process according to any one of clauses 23 to 36, wherein the process is used for cell labelling. 38. Use of the cell-permeable conjugate described in any one of paragraphs 1 to 20 for delivering a functional molecule to a cell, wherein the functional molecule is selected from the group consisting of dyes, drugs, metals, drug-metals, proteins, enzymes, antibodies, nucleic acids, polysaccharides, nuclear localization signals, nanoparticles, and combinations thereof. 39. Use of a cell-permeable conjugate according to any one of paragraphs 1 to 20 for cell penetration. 40. Use of a cell-permeable conjugate according to any one of paragraphs 1 to 20 for cell labeling. 41. A conjugate comprising: (a) at least one recombinant β-helical protein; (b) at least one linker; and (c) at least one nucleic acid molecule, wherein the length of the at least one recombinant β-helical protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm. 42. The conjugate according to paragraph 41, wherein the length of at least one recombinant beta helix protein is in the range of 10 nm to 15 nm and the width is in the range of 1 nm to 3 nm. 43. The conjugate according to paragraph 41 or 42, wherein the beta helix protein comprises one or more amino acid ladder structures selected from the group consisting of an arginine ladder, a lysine ladder, an asparagine ladder, an aspartic acid ladder, and a glutamic acid ladder. 44. The conjugate according to item 43, wherein, if present, the arginine ladder contains 10-20 arginine residues, the lysine ladder contains 10-30 lysine residues, the asparagine ladder contains 10-40 asparagine residues, the aspartic acid ladder contains 10-40 aspartic acid residues and the glutamic acid ladder contains 10-40 glutamic acid residues. 45. The conjugate of any one of clauses 41 to 44, wherein the beta helix protein has a total charge that is less than zero. 46. ​​The conjugate according to paragraph 45, wherein the β-helical protein has a total charge of -20 to -60. 47. β-helical proteins have a strength between 0.2 and 12 N / m as measured by atomic force microscopy. 2 47. The conjugate according to any one of items 41 to 46, having a β-helical structure (beta-helix) having a rigidity parameter K of 48. The conjugate according to any one of clauses 41 to 47, wherein the β-helical protein is a pentapeptide repeat protein. 49. The conjugate according to paragraph 48, wherein the beta helix protein comprises a tandem repeat pentapeptide having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5. 50. The conjugate according to any one of clauses 41 to 47, wherein the β-helical protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof. 51. The conjugate according to any one of clauses 41 to 50, wherein the linker is a linker molecule selected from the group consisting of polyethylene glycol (PEG), a peptide, a metal conjugate, a drug-metal conjugate, a DNA binding domain, a nucleic acid insert molecule and combinations thereof. 52. The conjugate according to paragraph 51, wherein when the linker molecule is a peptide, the peptide comprises amino acids selected from the group consisting of aliphatic amino acids, aromatic amino acids, and combinations thereof. 53. The conjugate of any one of clauses 41 to 52, wherein the linker is linked to the recombinant beta helix protein by covalent bonds, non-covalent bonds, and combinations thereof. 54. The conjugate according to paragraph 53, wherein the linker is linked to the recombinant beta-helical protein by an ester bond or an amide bond. 55. The conjugate according to any one of clauses 41 to 54, wherein the nucleic acid molecule comprises at least one gene of interest. 56. The conjugate according to paragraph 55, wherein the nucleic acid molecule is a plasmid. 57. The conjugate according to item 56, wherein the plasmid is a DNA plasmid or an RNA plasmid. 58. A conjugate described in any one of clauses 55 to 57, wherein the gene of interest encodes one or more molecules of a genome editing system. 59. Genome editing system a. RNA-guided endonuclease and / or guide RNA (gRNA); b. zinc finger nuclease (ZFN), c. Transcription Activator-Like Effector Nucleases (TALEN®); d. DNA-guided endonuclease and / or guide DNA; e. homing endonucleases, f. The conjugate of paragraph 58, wherein the conjugate is selected from the group consisting of integrase. 60. The conjugate according to any one of clauses 55 to 59, wherein the gene of interest encodes an RNA-guided endonuclease and / or a guide RNA (gRNA). 61. The conjugate according to clause 60, wherein the RNA-guided endonuclease is Cas9. 62. A process for transferring a nucleic acid molecule into a cell, the process comprising: a) linking a nucleic acid molecule to at least one recombinant beta helix protein via at least one linker to obtain a conjugate; b) contacting the conjugate with at least one cell; A process in which contacting the conjugate transfers the nucleic acid molecule into the cell, and the length of the recombinant beta helix protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm. 63. The process comprises, after step (b), c) detecting the entry of the conjugate into the cell. 64. The process according to paragraph 62 or 63, wherein the length of the recombinant beta helix protein is in the range of 10 nm to 15 nm and the width is in the range of 1 nm to 3 nm. 65. The process according to any one of clauses 62 to 64, wherein the beta helical protein comprises one or more amino acid ladder structures selected from the group consisting of an arginine ladder, a lysine ladder, an asparagine ladder, an aspartic acid ladder, and a glutamic acid ladder. 66. The process of paragraph 65, wherein, if present, the arginine ladder contains 10-20 arginine residues, the lysine ladder contains 10-30 lysine residues, the asparagine ladder contains 10-40 asparagine residues, the aspartic acid ladder contains 10-40 aspartic acid residues, and the glutamic acid ladder contains 10-40 glutamic acid residues. 67. The process according to any one of clauses 62 to 66, wherein the beta helical protein has a total charge that is less than zero. 68. The process according to paragraph 67, wherein the beta helical protein has a total charge of -20 to -60. 69. β-helical proteins have a strength of 0.2-12 N / m as measured by atomic force microscopy. 2 69. The process according to any one of paragraphs 62 to 68, wherein the nucleic acid has a β-helical structure (beta-helix) having a stiffness parameter K of 0.1 to 0.5. 70. The process according to any one of clauses 62 to 69, wherein the beta helical protein is a pentapeptide repeat protein. 71. The process according to paragraph 70, wherein the beta helical protein comprises a tandem repeat pentapeptide having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5. 72. The process according to any one of clauses 62 to 70, wherein the beta helix protein is represented by a sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof. 73. The process of any one of paragraphs 62 to 72, wherein the linker is selected from the group consisting of polyethylene glycol (PEG), peptides, metal conjugates, drug-metal conjugates, DNA binding domains, nucleic acid intercalating molecules, and combinations thereof. 74. The process according to paragraph 73, wherein when the linker molecule is a peptide, the peptide comprises amino acids selected from the group consisting of aliphatic amino acids, aromatic amino acids, and combinations thereof. 75. The process according to any one of clauses 62 to 74, wherein the linker is linked to the recombinant beta helix protein by covalent bonds, non-covalent bonds, and combinations thereof. 76. The process according to paragraph 75, wherein the linker is linked to the recombinant beta-helical protein by an ester bond or an amide bond. 77. The process according to any one of clauses 62 to 76, wherein the cell is selected from the group consisting of a eukaryotic cell or a prokaryotic cell. 78. The process according to any one of clauses 62 to 77, wherein the nucleic acid molecule comprises at least one gene of interest. 79. The process according to paragraph 78, wherein the nucleic acid molecule is a plasmid. 80. The process according to paragraph 79, wherein the plasmid is a DNA plasmid or an RNA plasmid. 81. The process described in any one of clauses 78 to 80, wherein the gene of interest encodes one or more molecules of a genome editing system. 82. Genome editing system a. RNA-guided endonuclease and / or guide RNA (gRNA); b. zinc finger nuclease (ZFN), c. Transcription Activator-Like Effector Nucleases (TALEN®); d. DNA-guided endonuclease and / or guide DNA; e. homing endonucleases, f. The process of paragraph 81, wherein the integrase is selected from the group consisting of integrase. 83. The process according to any one of clauses 78 to 82, wherein the gene of interest encodes an RNA-guided endonuclease and / or a guide RNA (gRNA). 84. The process according to paragraph 83, wherein the RNA-guided endonuclease is Cas9. 85. A genome editing complex for modifying a target polynucleotide comprising a recombinant beta helix protein linked to a plasmid encoding one or more molecules of a genome editing system, wherein the length of the beta helix protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm. 86. The genome editing complex described in item 85, wherein the recombinant beta helix protein comprises a tandem repeat pentapeptide having the consensus sequence (STAV)1(DN)2(LF)3(STR)4(G)5. 87. The genome editing complex described in paragraph 85, wherein the recombinant beta helix protein is represented by an sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof. 88. A genome editing complex described in any one of clauses 85 to 87, wherein the plasmid contains at least one gene of interest. 89. A genome editing complex described in any one of clauses 85 to 88, wherein the plasmid is a DNA plasmid or an RNA plasmid. 90. Genome editing system a. RNA-guided endonuclease and / or guide RNA (gRNA); b. zinc finger nuclease (ZFN), c. Transcription Activator-Like Effector Nucleases (TALEN®); d. DNA-guided endonuclease and / or guide DNA; e. homing endonucleases, f. A genome editing complex described in any one of clauses 85 to 89, selected from the group consisting of integrases. 91. A genome editing complex described in any one of clauses 85 to 90, wherein one or more molecules of the genome editing system are an RNA-guided endonuclease and / or a guide RNA (gRNA). 92. The genome editing complex of claim 91, wherein the RNA-guided endonuclease is Cas9. 93. Use of a conjugate described in any one of clauses 41 to 61 or a genome editing complex described in any one of clauses 85 to about 92 as a transfection agent. 94. Use of a conjugate described in any one of clauses 41 to 61 or a genome editing complex described in any one of clauses 85 to about 92 for gene therapy. 95. Use of a conjugate described in any one of clauses 41 to 61 or a genome editing complex described in any one of clauses 85 to about 92 for gene editing.

Claims

1. A genome editing complex for modifying a target polynucleotide comprising a recombinant beta helix protein linked to one or more molecules of a genome editing system, wherein the length of the beta helix protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm.

2. A genome editing complex for modifying a target polynucleotide comprising a recombinant beta helix protein linked to a plasmid encoding one or more molecules of a genome editing system, wherein the length of the beta helix protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm.

3. One or more molecules of the genome editing system a. RNA-guided endonuclease and / or guide RNA (gRNA); b. Zinc finger nucleases (ZFNs); c. Transcription Activator-Like Effector Nucleases (TALEN®); d. DNA-guided endonuclease and / or guide DNA; e. homing endonucleases, integrase.

4. The genome editing complex of claim 3, wherein one or more molecules of the genome editing system are an RNA-guided endonuclease and / or a guide RNA (gRNA).

5. The genome editing complex of claim 3 or claim 4, wherein the RNA-guided endonuclease is Cas9.

6. The genome editing complex of claim 3 or claim 4, wherein the gRNA has a sequence complementary to a target sequence in the target polynucleotide.

7. The genome editing complex of any one of claims 1 to 6, wherein the modification is an addition, deletion, or substitution of one or more nucleotides in the target polynucleotide.

8. The genome editing complex of any one of claims 1 to 7, wherein the beta helix protein has a roughly rectangular tip shape with a length in the range of 5 nm to 25 nm and a width in the range of 1 nm to 5 nm.

9. The genome editing complex of any one of claims 1 to 8, wherein the beta helix protein comprises one or more amino acid ladder structures selected from the group consisting of arginine ladder, lysine ladder, asparagine ladder, aspartic acid ladder, and glutamic acid ladder.

10. The genome editing complex of claim 9, wherein, if present, the arginine ladder contains 10 to 20 arginine residues, the lysine ladder contains 10 to 30 lysine residues, the asparagine ladder contains 10 to 40 asparagine residues, the aspartic acid ladder contains 10 to 40 aspartic acid residues, and the glutamic acid ladder contains 10 to 40 glutamic acid residues.

11. The genome editing complex of any one of claims 1 to 10, wherein the beta helix protein has a total charge that is less than zero.

12. The genome editing complex of claim 11, wherein the beta helix protein has a total charge of -20 to -60.

13. The beta helix protein has a strength of 0.2 to 12 N / m as measured by atomic force microscopy. 2 A genome editing complex described in any one of claims 1 to 12, having a beta helix structure (beta helix) with a rigidity parameter K of 0.01 to 0.

15.

14. The genome editing complex of any one of claims 1 to 13, wherein the beta helix protein is a pentapeptide repeat protein.

15. The beta helix protein has the consensus sequence (STAV) 1 (DN) 2 (LF) 3 (STR) 4 (G) 5 The genome editing complex of claim 14, comprising a tandem repeat pentapeptide having the following structure:

16. The genome editing complex of any one of claims 1 to 13, wherein the beta helix protein is represented by an sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, and combinations thereof.

17. A genome editing complex described in any one of claims 1 to 16, wherein the recombinant beta-helix protein is linked to one or more molecules of the genome editing system or the plasmid by non-covalent interactions.

18. The genome editing complex of claim 17, wherein the non-covalent interaction is selected from the group including hydrogen bonds, electrostatic interactions, van der Waals interactions, hydrophobic interactions, or combinations thereof.

19. The genome editing complex of any one of claims 1 to 17, wherein the recombinant beta helix protein is linked to one or more molecules of the genome editing system or the plasmid via a linker molecule selected from the group consisting of polyethylene glycol (PEG), ethylenediamine, peptides, metal conjugates, drug-metal conjugates, DNA binding domains, nucleic acid insertion molecules, and combinations thereof.

20. The genome editing complex of claim 19, wherein when the linker molecule is a peptide, the peptide comprises amino acids selected from the group consisting of aliphatic amino acids, aromatic amino acids, and combinations thereof.

21. The genome editing complex of claim 19 or 20, wherein the linker is linked to the recombinant beta-helix protein by a covalent bond, a non-covalent bond, or a combination thereof.

22. The genome editing complex of any one of claims 1 to 21, wherein the recombinant beta-helix protein is linked to one or more molecules of the genome editing system or the plasmid via an ester bond or an amide bond.

23. The genome editing complex of any one of claims 1 to 22, further comprising a signal sequence, the signal sequence directing the genome editing complex to a particular cell or part of a cell.

24. The genome editing complex of claim 23, wherein the signal sequence is selected from the group consisting of SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO:

17.

25. The genome editing complex of any one of claims 1 to 24, wherein the genome editing complex further comprises a phosphatidylcholine molecule.

26. The genome editing complex of any one of claims 23 to 25, wherein the genome editing complex transfers one or more molecules of the genome editing system or the plasmid to a location selected from the group consisting of an organelle, a nucleus, and a P-cadherin-overexpressing breast cancer cell.

27. The genome editing complex of any one of claims 1 to 26, wherein the genome editing complex is used for genome editing.

28. A method for preparing the genome editing complex of claim 1, comprising combining a recombinant beta helix protein with one or more genome editing system molecules, wherein the length of the beta helix protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm.

29. 29. The method of Claim 28, wherein the one or more genome editing system molecules are in a reaction buffer containing a molecule that stabilizes complex formation between the recombinant beta helix protein and the one or more genome editing system molecules.

30. A method for preparing the genome editing complex described in claim 2, comprising combining a recombinant beta helix protein with a plasmid, wherein the length of the beta helix protein is in the range of 5 nm to 25 nm and the width is in the range of 1 nm to 5 nm.

31. A pharmaceutical composition comprising a genome editing complex described in any one of claims 1 to 27.

Citation Information

Patent Citations

  • Cellular delivery and activation of polypeptide-nucleic acid complexes

    US20040176282A1

  • Cell penetrating peptide conjugates for delivering of nucleic acids into a cell

    US20130137644A1

  • Complete biosynthetic gene set for biosynthesis of albicidin, resistance genes, and uses thereof

    WO2004035760A2

  • Nucleic acid-like proteins

    WO2006113841A2

  • Proteinaceous pharmaceuticals and uses thereof

    WO2007038619A2